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ABSTRACT
Cellular Mechanisms of Effects of Sphingosine 1-Phosphate on
Vascular Endothelial Barrier
Mei Xu
Sphingosine 1-phosphate (S1P), a biologically active lipid, induces a myriad of
cellular events including enhancement of the endothelial barrier and assembly of
adherens junction proteins, VE-cadherin and catenins. The over all goal in this set of
studies was to investigate what cellular mechanisms contribute to S1P-induced
enhancement of the vascular endothelial barrier.
Since VE-cadherin contributes to the stabilization of the endothelial barrier, I
determined in the first study if the rapid, barrier-enhancing activity of S1P requires VEcadherin. Ca2+-dependent, homophilic VE-cadherin binding of endothelial cells, derived
from human umbilical veins and grown as monolayers, was disrupted with EGTA, an
antibody to the extracellular domain of VE-cadherin, or gene silencing of VE-cadherin
with small interfering RNA (siRNA). All three protocols caused a reduction in the
immunofluorescent localization of VE-cadherin at intercellular junctions, the separation
of adjacent cells, and a decrease in basal, endothelial electrical resistance. In all three
conditions, S1P rapidly increased endothelial electrical resistance. These findings
demonstrate that S1P enhances the endothelial barrier independently of homophilic VEcadherin binding. Junctional localization of VE-cadherin, however, was associated with
the sustained activity of S1P. Imaging with phase-contrast and differential interferencecontrast (DIC) optics revealed that S1P induced cell spreading and closure of
intercellular gaps. Pretreatment with Latrunculin B, an inhibitor of actin polymerization,
or Y-27632, a Rho kinase inhibitor, attenuated cell spreading and the rapid increase in
electrical resistance induced by S1P. I conclude that S1P rapidly closes intercellular
gaps, resulting in an increased electrical resistance across endothelial cell monolayers,
via cell spreading and Rho kinase and independently of VE-cadherin.
Based on the previous observation that S1P increases the localization of
junctional VE-cadherin as early as 10 min, I determined in the second study what
cellular mechanisms contributed to this increase. Because VE-cadherin dynamically
traffics between cell surface and cytoplasmic vesicles, I hypothesized that S1P can
regulate VE-cadherin trafficking. Immunofluorescence microscopy and a biotinylated
cell impermeable reagent were used to demonstrate internalized and cell surface VEcadherin. Endocytosis of VE-cadherin was induced by EGTA or VEGF. S1P decreased
EGTA-induced endocytosis and co-localization of internalized VE-cadherin with EEA 1,
a marker of early endosomes, and prevented and reversed the effect of VEGF. S1P
also increased the recovery of cell surface VE-cadherin after endocytosis by EGTA or
VEGF and increased the co-localization of internalized VE-cadherin with Rab11, a
marker of the recycling endosome. Bafilomycin A1, an inhibitor of recycling, and
microtubule inhibitors, taxol and colchicine, blocked the increase in junctional VEcadherin and the sustained increase in endothelial electrical resistance induced by S1P,
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the latter using the Ca2+-switch protocol. Bafilomycin A1 also prevented the increase in
recovery of cell surface VE-cadherin induced by S1P. When co-treated or post-treated
with VEGF, S1P blocked or reversed the increased interaction of VE-cadherin with βarrestin2, an endocytic adapter protein. I conclude that S1P stabilizes homophilic VEcadherin binding by decreasing endocytosis and increasing recycling of VE-cadherin,
the latter requiring microtubules.
In the third study, I investigated the cellular mechanisms contributing to the
regulatory effects of S1P on VE-cadherin trafficking. S1P increased co-localization and
interaction of p120 with VE-cadherin and increased biotinylated, cell surface VEcadherin and p120 with or without EGTA pretreatment. In addition, S1P enhanced the
co-localization of p120 with EGFP-tagged Rab11, a maker of recycling endosomes.
VEGF decreased the interaction of VE-cadherin with p120, and co-treatment or posttreatment with S1P blocked or reversed, respectively, this effect of VEGF. Interestingly,
S1P increased the interaction of p120 with kinesin, a motor protein that moves along
microtubules to transport vesicles.
In summary, I conclude that S1P enhances the endothelial barrier through
multiple ways: the rapid increase in endothelial barrier function is independent of VEcadherin, but requires Rho kinase and actin cytoskeleton-based cell spreading;
sustained enhancement of the barrier is related to an increase in junctional VE-cadherin
on which S1P has a novel effect—regulation of VE-cadherin trafficking, i.e. decreasing
endocytosis and increasing recycling of VE-cadherin. p120 possibly is involved in this
novel regulatory effect of S1P. Augmented interaction of p120 with kinesin by S1P may
facilitate transport of recycling VE-cadherin via microtubules.
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GENERAL INTRODUCTION
Endothelia adhere to each other through junctional structures to constitute a selective
semipermeable barrier. Disruption of vascular barrier integrity leads to increases of fluid,
solutes and proteins across endothelia, resulting in raised permeability which is linked to
normal biological processes, such as protein and fluid transport, inflammation, white cell
emigration, vasogenesis, as well as to many pathological processes, for example,
cancer metastasis and tumor angiogenesis. Two pathways, paracellular and
intracellular (vesicular), can account for the increased permeability. However, the
paracellular pathway is considered main pathway that contributes to the increased
permeability (45). However, the cellular mechanisms are unclear. Suggested
mechanisms that regulate the endothelial barrier include alterations in the integrity of
the junctions, the cytoskeleton, focal adhesions and cellular retraction/contraction and
relaxation. There are two main intercellular junctions between endothelial cells, tight
junctions and adherens junctions (5, 6, 16, 31). Distribution of tight junctions varies
along different segments of the vascular tree; tight junctions are well developed in
arteries and arterioles, but less organized in veins and postcapillary venules, which are
the primary sites for the extravasation of proteins and leukocytes (5).

Adherens

junctions (Figure 1) are formed by trans-membrane adhesion proteins of the cadherin
family, especially vascular endothelial (VE) cadherin, whose cytoplasmic tail is linked to
the actin cytoskeleton through β- and α-catenin. p120 catenin stabilizes VE-cadherin at
the junctional site by binding to the juxtamembrane domain of VE-cadherin (28, 63). VEcadherin consists of an extracellular domain with five homologous Ca2+-binding repeats
(EC1-EC5) that binds homophilically with VE-cadherin on an adjacent cell. It is known
that VE-cadherin is related to endothelial cell migration, survival, contact-induced
growth inhibition, vascular integrity and most notably, angiogenesis (17, 18, 42, 61).
Targeting the extracellular domain of VE-cadherin by specific antibodies, resulting in the
inhibition of angiogenesis, tumor growth and metastasis, is being developed as a
potential tool for cancer therapy (13, 14, 38). Interestingly, the loss of VE-cadherin
expression is related to a variety of pathologies, e. g. inflammation, angiogenesis and
endothelial-mesenchymal transdifferentiation (1, 10, 62). Thereby, the regulated
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changes in VE-cadherin level have important consequences on endothelial function and
pathophysiology. However, the cellular mechanisms that regulate cell surface
expression of VE-cadherin are poorly characterized.

Figure 1. Structure of adherens junctions (see text for details).

Adherens junctions are extensively investigated and are considered as a primary
regulated site by many endogenous and exogenous factors. Sphingosine 1-phosphate
(S1P) is a biologically active lipid growth factor (Figure 2) produced in many cells mainly
from platelets by the phosphorylation of sphingosine (55, 57), and also from
erythrocytes in a stimulus-independent manner (27). S1P exists in the circulation from
nanomolar to micromolar concentration, and its activities are regulated by association
with HDL (active form) or LDL (inactive form) (4). S1P distributes throughout the whole
cardiovascular system and plays a role in regulation of vascular tone. It is known that
S1P can induce a myriad of cellular events, such as cellular locomotion, vascular
maturation, and angiogenesis, as well as enhance the endothelial barrier (45, 46, 57).
S1P ligates G-protein coupled receptors, known are at least five S1P receptors of the
endothelial differentiation gene (Edg) family, and elicits a wide variety of intracellular
signals. Vascular endothelial cells express predominantly S1P-1 (Edg-1) and S1P-3
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Figure 2. Structure of S1P and its bio-activities.
(Edg-3) receptors (26, 37, 45, 46, 51). S1P induces a rapid and dose-dependent
increase in vascular endothelial barrier function as recorded by increases in transendothelial monolayer electrical resistance (20). For example, S1P induces a dosedependent increase in electrical resistance on bovine pulmonary arterial endothelial cell
(BPAEC) monolayers and a sustained increase in electrical resistance on human
umbilical vein endothelial cell (HUVEC) monolayers (Figures 3 and 4). S1P activates a
number of Rho family GTPases, such as Rac 1, Cdc42 and Rho A (20, 22, 35). S1Pelicited Rac 1 has been studied more extensively and has been linked to S1P-enhanced
barrier function (20, 58). However, we found that inhibition of Rho-kinase, a downstream
target of Rho A, also suppresses the S1P-increased electrical resistance in both human
and bovine cell lines. Therefore, the role of Rho A in S1P effects needs more study. It is
known that S1P organizes actin filaments into a strong cortical ring (45) and assembles
VE-cadherin and β-catenin at adherens junctions (20, 36, 47). How the actin
cytoskeleton or VE-cadherin contributes to the whole process of S1P effects is still
unclear. Furthermore, what cellular mechanisms contribute to S1P-assembled
membrane

VE-cadheren

have

not

yet

been

investigated.

S1P

and

other

lysophospholipids elevate intracellular calcium and trigger exocytosis in non-endothelial
and endothelial cells (36, 44, 47). S1P induces the exocytosis of Weibel-Palade bodies,
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and increases glutamate secretion in hippocampal neurons (29, 44). Possibly, S1P is
able to regulate exocytosis of internalized proteins.

Unpublished from Dr. Fred Minnear
Figure 3. S1P increases electrical

Figure 4. S1P increases electrical

resistance of BPAECs

resistance of HUVECs.

(see text for details).

(see text for details).

The cadherin family of proteins consists of epithelial (E)-, placental (P)-, neuronal
(N)-, muscle (M)-, and VE-cadherin and constitutively traffics between cell surface and
cytoplasm. Expression of cadherin at the plasma membrane is dynamically regulated by
cadherin turnover, which involves the processes of endocytosis, degradation, and
recycling. Cadherin first sorts into early endosomes, then goes through later endosomes
to be degraded by lysosomes, or recycled back to the cell surface via recycling
endosomes (Figure 5). Endocytosis of cadherins can be mediated through clathrindependent and clathrin-independent (caveolin-mediated) pathways and has been
observed during development, during epithelial to mesenchymal transition, and in
response to growth factors and tumorigenic signals (8, 9, 34, 65). The endocytosis and
recycling of E-cadherin, a member of the cadherin family expressed mainly on epithelial
cells, have been studied intensively by Stow et al. (8, 9, 33, 34). They found that 13% of
E-cadherin traffics dynamically. Depletion of extracellular calcium disrupted cell-cell
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contacts and induced endocytosis of E-cadherin, and repletion of calcium recovered
surface E-cadherins, which was inhibited by bafilomycin A1, an inhibitor of recycling
(34). They suggested that the pool of cell surface E-cadherin is constantly trafficking
through endocytic and recycling pathways. The trafficking of VE-cadherin may be
similar to that of E-cadherin. Endocytosis of VE-cadherin is an important regulated
mechanism that accounts for the amount of cell surface VE-cadherin. Down-regulation
of VE-cadherin initiates endothelial-mesenchymal transdifferentiation and is related to
atherogenesis (7, 19). Alexander et al. (2, 34) reported that a decrease in extracellular
calcium reduced cell surface VE-cadherin and

Figure 5. Trafficking pathway of E-cadherin (see text for details).
induced endocytosis of VE-cadherin in which protein kinase C is involved. Gavard and
Gutkind (21) reported that VEGF induces endocytosis of VE-cadherin through a βarrestin2, an adaptor protein for endocytosis, -dependent pathway which may contribute
to the increased permeability by VEGF. Furthermore, endocytosis of VE-cadherin
facilitates VEGF receptor2 internalization and its downstream signaling (32). However,
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the mechanisms related to regulation of trafficking of VE-cadherin are unclear, and
which endogenous factors that regulate VE-cadherin trafficking have not been
investigated. Interestingly, S1P at low concentration stabilized the vascular endothelial
barrier through regulation of N-cadherin trafficking (52), but whether S1P has capacity
to regulate VE-cadherin trafficking that contributes to S1P-induced enhancement of
endothelial barrier function is not clear. Our study is designed to investigate the cellular
mechanisms for the regulation of endothelial barrier function induced by S1P.
Recently, p120 was reported to play a core function for regulation of VEcadherin. p120 catenin, a member of the armadillo family of proteins and originally
identified as a substrate for Src and other tyrosine kinases, interacts with VE-cadherin
through its ARM domain and binds to the juxtamembrane domain (3). Iyer et al. (28)
reported that the interaction of VE-cadherin with p120 is crucial for stabilization of the
endothelial barrier, and p120 plays a major role in this stabilization; either a decrease or
increase in expression level of p120 results in disruption of the endothelial barrier. Xiao
et al. (15, 63-65) reported that p120 acts as a set point for cadherin expression in
mammalian endothelial cells. The loss of p120 causes the internalization of E-cadherin
and delivery to lysosomes for proteolytic degradation. Contrastingly, over-expression of
p120 strongly inhibited clathrin-dependent endocytosis of VE-cadherin. Interestingly,
there is a reported interaction of p120 with kinesin, a motor protein, via a segment of the
N-terminus of p120 that binds to kinesin heavy chain. Based on this interaction, p120kinesin regulates p120 localization and function, and furthermore facilitates the transport
of the cadherin-catenin complex to intercellular junctions (12, 67). However, p120 is not
necessary for proper delivery of new biosynthesized VE-cadherin to the cell membrane
(63). One goal of my studies is to investigate whether or not p120 is involved in VEcadherin trafficking induced by S1P.
Rab proteins, a large family of monomeric small GTPases, distribute to distinct
intracellular compartments, and in their active form, coordinate with their effectors to
regulate vesicle sorting, transportation, and fusion with membranes (53, 59, 60, 68). As
mentioned above, cadherin turnover mainly includes endocytosis, recycling, as well as
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degradation of which, respectively, are related to early endosomes, recycling
endosomes, and later endosomes and lysosomes. Rab5, works together with its
effector, EEA1 (early endosome antigen 1) to regulate the transportation of clathrincoated-vesicles from the plasma membrane to early endosomes as well as homotypic
fusion of early endosomes. Rab7 localizes at later endosomes and Rab11 and Rab4
regulate the recycling process. Papers by Moore and Stow (41, 48) have reported that
Rab11 works as an intermediate compartment for regulation of recycling of beta2adrenergic receptors and the post-Golgi trafficking and exocyotosis of E-cadherin.
Accordingly, Rab proteins are used as markers for specialization of distinct endosomes.
Other proteins, such as soluble NSF attachment receptors (SNAREs), Vamp3, etc. also
work in partnership with the function of Rab GTPases.
Vascular endothelial growth factor (VEGF), formerly known as a vascular
permeability factor, is essential for vasculogenesis and angiogenesis through ligating to
its receptor, VEGFR-2. Dejana and co-workers (32) reported that VEGF induced the
internalization of VEGFR-2, which was facilitated in the absence of cell surface VEcadherin. Furthermore, engaged homophilic binding of VE-cadherin retained VEGFR-2
at the cell membrane and prevented its internalization into signaling compartments.
Recently, it was reported that the VEGF-induced increase in vascular permeability is
related to VEGF-induced endocytosis of VE-cadherin (21, 32). These studies outline the
following sequence of events: VEGF binds to VEGFR-2 and activates Src which
activates Rac then p21-activated kinase (PAK), which phosphorylates a highly
conserved motif within the intracellular tail of VE-cadherin, followed by recruitment of βarrestin2 to the serine-phosphorylated VE-cadherin, thereby promoting clathrindependent endocytosis of VE-cadherin. Interestingly, S1P is a vascular barrier
enhancer. Based on the opposite role of S1P, I hypothesize that S1P is able to
suppress the VEGF-induced increase in vascular permeability by regulating the
interaction of β-arrestin2 with VE-cadherin, which in turn modulates the endocytosis of
VE-cadherin.
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Protein trafficking transports via actin cytoskeletons or microtubules or both (25,
49). Microtubules, together with the microtubule-based motor proteins, kinesin and
dynein, play an essential role in membrane trafficking events involved in endocytosis,
transcytosis, etc. (25, 39, 40, 43, 50, 66). As aforementioned, p120-kinesin interaction
facilitates the transport of the cadherin-catenin complex to cell-cell contacts via
microtubules in living fibroblasts (43). Interestingly, S1P was reported to increase
polymerization of microtubules and facilitate N-cadherin trafficking along it (52, 66).
However, if trafficking of VE-cadherin goes through microtubules, it has not been
characterized. In this dissertation, two types of microtubule inhibitors, taxol (inhibits
depolymerization) and colchicine (inhibits polymerization), were used to investigate the
effects of microtubules on VE-cadherin trafficking.
As stated above, S1P enhances endothelial barrier function as assessed as an
increase in electrical resistance by using Electric Cell-substrate Impedance Sensing
(ECIS) technology (Figure 6). This patented technique, invented by Drs. Ivar Giaever
and Charles R. Keese (Applied Biophysics, Inc), is one of the main techniques used in
my dissertation and now is widely applied to measure, in real time, cell motility, cell
growth, cell spreading, wound healing and barrier function via constantly monitoring the
changes in impedance of a small electrode to AC current flow (11, 23, 24, 54, 56). The
current flows between a small electrode and a larger counter electrode using normal
culture medium as the electrolyte. Cells are seeded on a gold-coated small electrode
(250 µm diameter) in ECIS culture wells. The electrical resistance measured is that of
those cells. When cells attach to the culture wells, the current flows in the spaces under
and between the cells, as the cell membranes are essentially insulators. A constant
current of 1 μA is supplied by a 1-V, 4,000-Hz alternating current through a 1-MΩ
resistor. Finally, changes in voltage between the small electrode and the large counter
are monitored by the lock-in amplifier, stored, and then calculated as resistance by the
computer. On confluent endothelial monolayers, an increase in electrical resistance
indicates cell-cell contacts becoming tighter, i. e. enhancing endothelial barrier. In
contrast, decreased electrical resistance means loosened cell-cell contacts.
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To study protein trafficking, quantitative measurements of internalized and

Figure 6. ECIS monitors the resistance between cells (see text for details).
cell surface VE-cadherin are essential. A biotinylation protocol (Figure 7) was adopted
to measure internalized and cell surface proteins and has been frequently used by Stow
et al. in their studies on trafficking of E-cadherin (8, 33, 34). Sulfo-NHS-SS-biotin is a
water-soluble, membrane impermeable and cleavable biotin reagent that binds to
primary amines (lysine) through its NHS ester. Since biotin forms a strong non-covalent
bond when it interacts with avidin or streptavidin, sulfo-NHS-SS-biotin is good for
purification and extraction of proteins. For measurement of internalized proteins,
labeling cell surface proteins with sulfo-NHS-SS-biotin is the first step, followed by
designated treatments to induce endocytosis. Glutathione disrupts S-S bonds in sulfoNHS-SS-biotin and removes biotin from the cell surface. Internalized proteins resistant
to the glutathione wash and still bound to sulfo-NHS-SS-biotin are collected by
streptavidin beads. However, the measurement of cell surface proteins is somewhat
different. After treatments, whole cell surface proteins are labeled with sulfo-NHS-SSbiotin and then collected by streptavidin. Comparing these two methods, the glutathione
wash is the pivotal step.
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In summary, the cellular mechanisms of the effects of S1P on endothelial barrier
function were investigated through measurements of changes in endothelial electrical
resistance, function of homophilic VE-cadherin binding, junctional localization of VEcadherin, cell spreading, interaction of VE-cadherin with other proteins, and trafficking of
VE-cadherin.

Figure 7. Biotinylation protocol (see text for details).
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OBJECTIVES
Endothelia lining the inner surface of blood vessels constitute a selective
semipermeable barrier. Changes of barrier integrity are linked to many physiological
and pathological processes.

For example, disruption of the vascular barrier by

inflammatory stimuli increases vascular permeability to fluid and solutes, which can
result in edema (30). Angiogenesis also requires physiological changes of the
endothelial barrier (6, 31). The cellular mechanisms that regulate the endothelial barrier
are not completely clear and may involve a number of cellular processes. Adherens
junctions containing vascular endothelial (VE)-cadherin, other cadherins and catenins
(α, β, γ and p120) have been studied extensively and have been considered as primary
regulated sites by various endogenous and exogenous factors. Calcium-dependent VEcadherin mediates cell-cell contacts and plays an essential role in stabilization of the
vascular barrier. It has been recognized that sphingosine 1-phosphate (S1P), a
biologically active lipid released mainly by active platelets, enhances barrier function as
measured by an increase in trans-endothelial electrical resistance (20), and increases
the localization of VE-cadherin and β-catenin at the adherens junctions (36, 46).
However, the cellular mechanisms that contribute to S1P effects on endothelial barrier
function, especially on regulating VE-cadherin, are not fully clear.
The goal of my research is to identify what cellular mechanisms contribute to the
S1P-induced enhancement of barrier function.
Study 1. To determine if VE-cadherin is involved in the S1P-induced enhancement of
electrical resistance.
•

The primary objective is delineate the involvement of homophilic VE-cadherin
binding and cell spreading in the enhancement of endothelial barrier function
induced by S1P.

Study 2. To investigate S1P effects on the maintenance of endothelial barrier function
through regulating trafficking of VE-cadherin.
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•

Hypothesis 1. S1P enhances the localization of VE-cadherin at adherens
junctions by increasing recycling and decreasing endocytosis of VE-cadherin. By
these processes, S1P stabilizes the localization of VE-cadherin.

•

Hypothesis 2. S1P rescues the VEGF-induced decrease in membrane VEcadherin by blocking the VEGF-induced β-arrestin2-related endocytosis of VEcadherin.

Study 3. To investigate if p120 is involved in regulated VE-cadherin trafficking by S1P.
•

Hypothesis. Increased interaction of p120 with VE-cadherin by S1P facilitates
VE-cadherin trafficking.
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Study 1

Sphingosine 1-phosphate rapidly increases endothelial barrier
function independent of VE-cadherin but requires cell spreading and
Rho kinase

Keywords: permeability, microscopy, electric cell-substrate impedance
sensing, human umbilical endothelial cell.
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ABSTRACT

Sphingosine 1-phosphate (S1P) rapidly increases endothelial barrier function and
induces the assembly of adherens junction proteins, VE-cadherin and catenins. Since
VE-cadherin contributes to the stabilization of the endothelial barrier, I determined if the
rapid, barrier-enhancing activity of S1P requires VE-cadherin.

Ca2+-dependent,

homophilic VE-cadherin binding of endothelial cells, derived from human umbilical veins
and grown as monolayers, was disrupted with EGTA, an antibody to the extracellular
domain of VE-cadherin, or gene silencing of VE-cadherin with small interfering RNA
(siRNA). All three protocols caused a reduction in the immunofluorescent localization of
VE-cadherin at intercellular junctions, the separation of adjacent cells, and a decrease
in basal, endothelial electrical resistance. In all three conditions, S1P rapidly increased
endothelial electrical resistance. These findings demonstrate that S1P enhances the
endothelial barrier independently of homophilic VE-cadherin binding.

Junctional

localization of VE-cadherin, however, was associated with the sustained activity of S1P.
Imaging with phase-contrast and differential interference-contrast (DIC) optics revealed
that S1P induced cell spreading and closure of intercellular gaps. Pretreatment with
Latrunculin B, an inhibitor of actin polymerization, or Y-27632, a Rho kinase inhibitor,
attenuated cell spreading and the rapid increase in electrical resistance induced by
S1P. I conclude that S1P rapidly closes intercellular gaps, resulting in an increased
electrical resistance across endothelial cell monolayers, via cell spreading and Rho
kinase and independently of VE-cadherin.
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INTRODUCTION
Vascular endothelia act as a restrictive barrier and as such regulate many
biological processes such as protein and fluid transport, inflammation, white cell
emigration, and angiogenesis. Disruption of the endothelial barrier leads to
accumulation of fluid and macromolecules in the interstitial space, resulting in edema
and dysfunction of tissues and organs (1, 11, 14). The cellular mechanism(s) that
regulates the endothelial barrier is not known and may involve a number of cellular
processes. Proposed mechanisms include alterations in the integrity of the junctions,
the cytoskeleton, and focal adhesions and cellular retraction/contraction and relaxation
(1, 11, 14). Tight junctions comprised of occludins, claudins, ZO-1, etc. impart the
barrier characteristics of epithelial cells; however, their importance with respect to
endothelial barrier function requires further study (1). The endothelial adherens junction,
containing vascular endothelial (VE)-cadherin, other cadherins, and catenins, has been
studied extensively, and modifications to VE-cadherin profoundly affect the integrity of
the endothelial barrier. For example, antibodies directed toward the extracellular domain
of VE-cadherin increased the permeability of endothelial cell monolayers (4) and the
vascular permeability in heart and lungs of mice (5).
Sphingosine 1-phosphate (S1P) is a biologically active lipid released from a
number of cells, notably platelets, and is present in blood and serum at nanomolar to
micromolar concentrations. S1P enhances the barrier function of cell monolayers (8),
prevents the increase in hydraulic conductivity induced by platelet-activating factor in
single venular microvessels (17), and attenuates the increase in pulmonary edema in
mice and dogs subjected to intra-tracheal endotoxin (12, 19). In addition, S1P enhances
the localization of VE-cadherin and the catenins, α, β, and γ, at endothelial junctions
within 30 to 60 min of treatment (9, 13). S1P has also been shown to induce membrane
ruffling and cell spreading of single endothelial cells (6, 18) and lamellipodia formation
and cell spreading at the leading edge of wounded, endothelial cell monolayers (25).
Cell spreading is also induced by cAMP-enhancing agents that are well known to rapidly
tighten the endothelial barrier (15, 22).
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Therefore, the primary objective of the study was to delineate the involvement of
homophilic VE-cadherin binding and cell spreading in the enhancement of endothelial
barrier function induced by S1P. VE-cadherin binding was disrupted by using three
different methodologies, addition of EGTA to the cell culture medium to lower
extracellular Ca2+, addition of an antibody to the extracellular domain of VE-cadherin,
and gene silencing of VE-cadherin with small interfering RNA (siRNA). Imaging of live
cells by phase-contrast and differential interference-contrast (DIC) optics documented
changes in cell shape. Evidence of closure of intercellular gaps, induced by the
treatment of EGTA, was demonstrated microscopically and by an increase in
endothelial electrical resistance. Since actin polymerizes at the leading edge of
spreading cytoplasm (21), S1P reorganizes actin to the cell periphery (8), and activation
of the small GTPase Rho has been implicated in the spreading of single endothelial cells
by S1P (18), I further determined if inhibitors of actin polymerization and Rho kinase, an
effector of Rho, would impede the spreading of endothelial cells by S1P.
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MATERIALS AND METHODS

Materials. S1P was purchased from Avanti Polar Lipids (Alabaster, AL). Gentamicin
sulfate was from ICN Biomedicals, Inc. (Aurora, OH). Newborn calf serum and bovine
brain extract were from Cambrex Corporation (East Rutherford, NJ). Prolong Gold antifade reagent, Alexa Fluor-labeled secondary antibodies and Alexa Fluor-labeled
phalloidin were from Invitrogen Molecular Probes (Eugene, OR). Gold-coated ECIS
(Electrode Cell-substrate Impedance Sensing) electrodes were from Applied Biophysics
(Troy, NY).

Rabbit anti-human VE-cadherin antibodies were purchased from

USBiological (Swampscott, MS) and Axxora (San Diego, CA). Goat anti-human VEcadherin antibody and normal rabbit IgG were from Santa Cruz Biotechnology (San
Diego, CA). Horseradish peroxidase conjugated secondary antibodies were purchased
from Chemicon International (Temecula, CA).

Control (scrambled) siRNA and VE-

cadherin siRNA (Smartpool) were from Dharmacon (Chicago, IL).

Nitrocellulose

membranes and ECL (enhanced chemiluminescence) Western blotting detection
reagents were from Amersham Biosciences (Buckinghamshire, England).

All other

chemicals were from Sigma-Aldrich (St. Louis, MO).
Cell Culture. Endothelial cells were isolated from human umbilical veins (HUVEC) with
1 mg/ml of type I collagenase and grown in MCDB-131 (MCDB) culture medium
containing 5% (v/v) human serum, 20% (v/v) newborn calf serum, 7.5 μg/ml of
endothelial cell growth supplement, 4.5 μg/ml of bovine brain extract, 25 μg/ml of
porcine intestinal heparin, and 50 μg/ml of gentamicin sulfate. HUVECs (passages 2-8)
were grown to confluence (2 d) in a humidified incubator maintained at 37° C and 5%
CO2.

Before treatment with S1P, MCDB containing 25% serum was replaced with

serum-free MCDB, and the cells monolayers were allowed to equilibrate for 2 h in an
incubator.

Transendothelial electrical resistance.

To assess changes in endothelial barrier

function, electrical resistance was measured continuously across HUVEC monolayers
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by ECIS (7; 16).

Briefly, HUVECs (80,000-100,000 cells) were seeded onto ECIS

cultureware (0.8 cm2/well) precoated with 0.2% gelatin. The measured electrical
resistance was of those cells located on the small gold electrode (5 x 10

4

cm2) in each

of the wells. The culture medium was the electrolyte, and the small gold electrode,
covered by confluent endothelial cells, and a larger gold counter-electrode (~2 cm2)
were connected to a phase-sensitive, lock-in amplifier. A constant current of 1 μA was
supplied by a 1-V, 4000-Hz alternating current through a 1-MΩ resistor. Changes in
voltage between the small electrode and the large counter electrode were monitored by
the lock-in amplifier, stored, and then calculated as resistance by the computer. The
small size of the cell-seeded electrode is the critical feature of the system.

When

electrodes of 10-3 cm2 or smaller are used, the impedance at the small electrode
dominates the system, allowing for assessment of the morphological changes of the
cells located at this interface. Electrical resistance of the bare electrode is ~2,000 ohms
and increases to 10,000 ohms or greater when HUVECs have become confluent. If the
electrical resistance of the endothelial cell-covered electrode is 10,000 ohms, as
depicted in Figure 4, and is corrected for electrical resistance of the bare electrode
(2,000 ohms), then multiplying 8,000 ohms times the electrode surface area of 5x10-4
cm2 yields a basal electrical resistance across the HUVEC monolayer of 4 ohms•cm2,
similar to 5 ohms•cm2 as reported using a Ussing-type recording chamber (24).
EGTA Protocol (Ca2+-switch protocol). HUVEC monolayers were treated with 2 mM
EGTA (ethylene glycol-bis(2-aminoethylether)-N,N,N’,N’-tetraacetic acid) for 10 min to
chelate extracellular Ca2+, followed by 1) no treatment, 2) adding 400 μl of fresh MCDB
containing 1.6 mM Ca2+ to restore extracellular Ca2+, 3) adding only 1 μM S1P (in 1 μl)
without restoring extracellular Ca2+), and 4) adding S1P and MCDB together.

For

treatments 1 and 3 above, EGTA was present in the cell culture medium for the entire
experimental period. For treatments 2 and 4 above, culture medium was withdrawn at
10 min after the administration of EGTA and before the addition of fresh MCDB. S1P
was solubilized in methanol with sonication and transferred to microcentrifuge tubes
(0.5 ml). Methanol was subsequently removed by nitrogen, and the tubes with S1P
were stored at -20° C. S1P was reconstituted in TBS for experimentation.
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Immunofluorescence confocal microscopy.

After the various treatments, HUVECs

monolayers were rinsed with phosphate buffered saline containing Ca2+ and Mg2+
(PBS+/+). Cells were fixed with 3.7% paraformaldehyde for 15 min, permeabilized for 5
min in cytoskeletal buffer (10 mM PIPES at pH 6.8, 3 mM MgCl2, 100 mM NaCl, and
300 mM sucrose) containing 0.5% Triton X-100, then incubated for 20 min with 5%
BSA. Rabbit anti-human VE-cadherin polyclonal antibody was added to the cells for 60
min, followed by Alexa Fluor 488- or 594-labeled goat anti-rabbit IgG and Alexa Fluor
488-labeled phalloidin to identify actin filaments, and the cells were rinsed several times
with PBS+/+. Cells were mounted with Prolong Gold anti-fade reagent. Images were
generated by confocal laser scanning with a Zeiss LSM 510 confocal microscope.
When comparing images, the fluorescent signals were measured at emission
wavelengths of 488 and 594 nm with the same pinhole (less than 1 μm), the same
detector gain, and the same amplifier offset.

RNA Interference.

VE-cadherin siRNA was transiently transfected into HUVECs by

electroporation with the Nucleofector I device (Amaxa Biosystems, Berlin, Germany).
Briefly, 90% confluent cell monolayers were trypsinized and individual cells counted.
After centrifugation, 1.5x106 cells were resuspended in 100 μl of a Nucleofector solution
(7.25 mM ATP, 12 mM MgCl2⋅6H2O, 88 mM KH2PO4, 14 mM NaHCO3, and 2 mM
glucose at pH 7.4) with 400 pmoles of VE-cadherin siRNA or control, scrambled siRNA.
The cells in solution were transferred immediately to a cuvette and electroporated in the
Nucleofector apparatus using the U-01 program. Transfected cells were recovered with
warm, fresh MCDB for 5 min, and seeded immediately on 0.2% gelatin-coated ECIS
wells and monitored for electrical resistance or seeded on 24-well tissue culture plates
and placed in an incubator for 2 d until used for microscopy or Western blot
experiments. The protein level of VE-cadherin was quantified from Western blots by
densitometry after normalization to β-actin as a protein loading control.
Immunoblotting. Cells were washed 2x in ice-cold PBS, lysed in RIPA buffer (15 mM
NaCl, 50 mM Tris, 1% NP-40, and 0.5% sodium deoxycholate) containing 2 mM EGTA,
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phosphatase inhibitors (1 mM sodium vanadate and 1 mM phenylmethanesulfonyl
fluoride), and proteinase inhibitors (5 μg/ml of aprotinin and 2 μg/ml of leupeptin).
Samples were clarified by centrifugation at 14,000 rpm for 10 min at 4° C. Proteins
were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDSPAGE)

and

transferred

to

Nitrocellulose

membrane

using

a

mini-Protean

electrophoresis system. Protein blots were probed with indicated primary antibodies,
followed by the appropriate horseradish peroxidase-conjugated secondary antibody,
and developed by enhanced chemiluminescence.
Cell Spreading. HUVECs were grown to confluence in 35-mm glass bottom culture
dishes or Delta T culture dishes. Cells were placed in serum-free MCDB with 20 mM
HEPES for 2 h.

For phase-contrast microscopy, 35-mm glass bottom dishes were

inserted into a temperature (37o C) and humidified controlled chamber mounted on the
stage of a Zeiss AxioVert 200M microscope, and cells were viewed through a 20X
phase-contrast objective, and 1.6X Optovart to increase magnification.

For DIC

microscopy, Delta T culture dishes, with a temperature-controlled bottom, were placed
on the stage of a Nikon Eclipse TE 2000-5 microscope, and cells were viewed through a
20X DIC optical lens. Phase-contrast images were obtained using a Zeiss AxioCam
camera and Axiovision software, and DIC images were processed using a Nikon
camera and Metamorph software.
Statistics. All values are presented as means ± SE. A minimum of three experiments
was conducted for ECIS experiments and five for microscopy experiments. Data on
electrical resistance were analyzed with a 2-way analysis of variance with repeated
measures (26). Differences between treatments at specific time points were analyzed
further with a Bonferroni post-test. Statistical significance was set at P<0.05.
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RESULTS

S1P rapidly increased endothelial electrical resistance independently of
homophilic VE-cadherin binding. S1P has been reported to increase the localization of

Figure 1. S1P rapidly increased endothelial electrical resistance after chelation of
extracellular Ca2+ with EGTA. Ca2+ in culture media of cell monolayers, derived from human
umbilical vein endothelial cells (HUVECs), was chelated with 2 mM EGTA. Cells were then
not treated (EGTA, open circles) or treated (arrow) with MCDB-131 (MCDB, open squares)
to restore extracellular Ca2+, S1P alone (1 μM in 1 μl, closed triangles), or S1P and MCDB
(closed circles). EGTA-containing medium was removed before addition of MCDB without or
with S1P but remained for cell monolayers not treated or treated with S1P alone. a)
Continuous data recorded over 180-min time period; b) values at 10 min after treatments with
MCDB, S1P, or MCDB+S1P; c) values at 140 min after treatments. Note that S1P rapidly
increased endothelial electrical resistance (ER) without or with addition of MCDB (a,b),
whereas sustained activity of S1P required MCDB (a,c). n=6 in each group; *P<0.05 from
EGTA; #P<0.05 from EGTA:MCDB in (b) and EGTA:S1P in (c).

VE-cadherin at intercellular junctions (9; 13). To determine whether this increase is
responsible for the rapid increase in endothelial electrical resistance induced by S1P,
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Figure 2. S1P enhanced the junctional localization of VE-cadherin and peripheral actin. EGTA
protocol outlined in Figure 1 was repeated for visualization of VE-cadherin and filamentous
actin (F-actin) at cell periphery of same cells. a,b) Representative micrographs depicted are of
HUVEC monolayers at 10 min (a) or 140 min (b) after treatment with MCDB, S1P, or S1P plus
MCDB. In fixed and permeabilized cell monolayers, VE-cadherin was visualized by incubation
with rabbit anti-human VE-cadherin polyclonal antibody and Alexa Fluor 594-labeled goat antirabbit secondary antibody, and filamentous actin was visualized with Alexa Fluor 488-labeled
phallodin. Note that treatment with S1P plus MCDB increased presence of VE-cadherin at
intercellular junctions (a), that S1P alone and S1P plus MCDB reorganized actin to cell
periphery (a), and that presence of junctional VE-cadherin was maintained for 140 min only
after treatment with MCDB or S1P plus MCDB. Scale bars, 10 μm.

homophilic VE-cadherin binding was disrupted by three different protocols: 1) addition
of 2 mM EGTA to chelate extracellular Ca2++, 2) addition to the culture medium of an
antibody to the extracellular domain of VE-cadherin, and 3) gene silencing of VEcadherin.

In all three protocols, S1P (1 μM) rapidly increased electrical resistance
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across endothelial cell monolayers in association with a reduction in the localization of
VE-cadherin at intercellular junctions.
Addition of EGTA to the cell culture medium caused a precipitous decrease in
endothelial electrical resistance (Fig. 1a) and a loss of VE-cadherin at intercellular
junctions (Fig. 2a). After 10 min of incubation with EGTA, cell monolayers were either
not treated or treated with MCDB (containing 1.6 mM) to replenish extracellular Ca2+,
S1P alone (1 μM in 1 μl) , or MCDB plus S1P. Therefore, cell monolayers not treated or
treated with S1P alone were exposed to EGTA for the entire experimental period;
whereas, those cell monolayers treat with MCDB or S1P+MCDB were exposed to
concentrated EGTA for only 10 min. Endothelial electrical resistance did not change
with no treatment and increased slightly then slowly returned to the pre-EGTA level with
the addition of MCDB (Fig. 1a, b). In contrast, electrical resistance increased rapidly
within 10 min to the pre-EGTA level or above upon treatment, respectively, with S1P
without (Fig. 1a, b) or with MCDB (Fig. 1a, b).

The identical EGTA protocol was

repeated to visualize VE-cadherin and filamentous actin by confocal microscopy (Fig.
2). A characteristic of the S1P response is a reorganization of actin to the cell periphery
(8), which was also observed in the present study within 10 min of treatment with S1P
or S1P plus MCDB subsequent to the addition of EGTA (Fig. 2a).

In control cell

monolayers, VE-cadherin appeared prominently at intercellular junctions.

Twenty

minutes (also 10 min, data not shown) after EGTA treatment, there was a reduction in
junctional VE-cadherin and an apparent increase in VE-cadherin in the cytoplasm (Fig.
2a, EGTA:no treatment). In addition, gaps were present between adjacent cells. After
replacement of extracellular Ca2+ with the addition of fresh MDCB, VE-cadherin was
observed to some extent at intercellular junctions and there was a reduction in
cytoplasmic VE-cadherin within 10 min (Fig. 2a). The effect of S1P on junctional VEcadherin was dependent on whether MCDB was added to restore extracellular Ca2+.
After treatment with S1P alone for 10 min, very little VE-cadherin was observed at
intercellular junctions. Upon treatment with S1P plus MCDB, the intensity of
immunofluorescent staining of VE-cadherin at cell borders was greater at 10 min than
with treatment of MCDB alone and was similar to immunofluorescent staining of control
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cell monolayers. Both treatments, S1P alone and S1P plus MCDB, resulted in the
closure of most of the intercellular gaps. These microscopy and functional findings
provide correlative evidence that S1P rapidly closes preexisting gaps between cells and
increases endothelial electrical resistance in association with an absence of VEcadherin at intercellular junctions.

Figure 3. S1P rapidly increased endothelial electrical resistance in presence of antibody to
extracellular domain of VE-cadherin. Homophilic VE-cadherin binding was also disrupted by
incubation with an antibody (Ab, CD144) to extracellular domain of VE-cadherin. HUVEC
monolayers were incubated for 60 min with VE-cadherin antibody or normal rabbit
immunoglobuIin (IgG), then treated with S1P. Note that endothelial electrical resistance
decreased after 60-min administration of VE-cadherin antibody (open bar) and that S1P
increased electrical resistance (peak response) in both treated groups (closed bars). n=4 in
each group; *P<0.05 vs. indicated group.

Similar results were obtained by the addition of an antibody to the extracellular
domain of VE-cadherin (Fig. 3) or gene silencing of VE-cadherin (Fig. 4). Addition to
the culture medium of an extracellular VE-cadherin antibody resulted in a decrease in
basal, endothelial electrical resistance (Fig. 3) and a discontinuous appearance of VEcadherin at intercellular junctions (data not shown) as compared to the addition of
normal rabbit immunoglobin G (IgG). S1P rapidly and transiently increased electrical
resistance of cell monolayers incubated with the VE-cadherin antibody as well as the
control IgG (Fig. 3). Transient transfection of VE-cadherin siRNA reduced the protein
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Figure 4. S1P increased endothelial electrical resistance after gene silencing of VE-cadherin.
HUVEC monolayers (90% confluence) were transiently transfected by electroporation with VEcadherin siRNA or scrambled siRNA. Transfected cells were seeded on 24-well culture
dishes and incubated for 2 d until used for microscopy (a,b) or Western blot (c) experiments or
seeded on ECIS wells for continuous measurement of electrical resistance (d). a,b) VEcadherin was visualized at 48 h by incubation with CD144 antibody to VE-cadherin and Alexa
Fluor 594-labeled goat anti-rabbit secondary antibody. d) Continuous measurement of
endothelial electrical resistance for ~48 h after electroporation of VE-cadherin siRNA (open
triangles) or scrambled siRNA (close circles) and after treatment with S1P (arrow); MCDB with
25% serum was replaced with serum-free MCDB at 46 h. e) EGTA was administered for 10
min to cell monolayers already transfected with either VE-cadherin siRNA (open triangles) or
scrambled siRNA (closed circles) then treated with S1P plus MCDB (arrow). f) Cells were
viewed directly on ECIS wells at end of experiment by incubation with rabbit anti-human VEcadherin polyclonal antibody and Alexa Fluor 594-labeled goat anti-rabbit secondary antibody.
Note that S1P increased endothelial electrical resistance in both transfected groups (d) and
that increased electrical resistance was maintained only in scrambled siRNA group in which
VE-cadherin was localized to cell borders (f, upper). n=5 in each group; *P<0.05 vs. control
groups. Scale bars, a,b = 10 μm; f = 20 μm.
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level of VE-cadherin by ~90% (Fig. 4c) and the localization of VE-cadherin at
intercellular junctions (Fig. 4a, scrambled siRNA, versus Fig. 4b, VE-cadherin siRNA)
within 48 h. As with the other two protocols, gene silencing of VE-cadherin caused a
decrease in basal, endothelial electrical resistance (Fig. 4d), which was apparent within
24 h, and did not affect the rapid increase in endothelial electrical resistance induced by
S1P.

Moreover, S1P was still active in those cell monolayers exposed to a

combinatory protocol of reduction of VE-cadherin protein by gene silencing followed by
chelation of extracellular Ca2+ with EGTA (Fig. 4e).

S1P augmented the junctional localization of VE-cadherin.

Within 10 min of

treatment, S1P was observed to increase the localization of VE-cadherin at intercellular
junctions (Fig. 2a). This observation was made only when S1P was administered in the
presence of extracellular Ca2+. Following the administration of EGTA (Fig. 2a), more
VE-cadherin was present at intercellular junctions with the treatment of S1P and MCDB,
the latter to restore extracellular Ca2+, as compared to the treatment of MCDB or S1P
alone.

This increased localization was also observed under normal, cell culture

conditions (Fig. 6b).

Sustained increase in endothelial electrical resistance induced by S1P was
associated with localization of VE-cadherin. Using the EGTA protocol, there was a
sustained increase in endothelial electrical resistance (Fig. 1a,c; also Figs. 4e and 7b)
and VE-cadherin was localized to intercellular junctions (Fig. 2b and 4f upper) at 140
min after S1P was administered in combination with MCDB.

Endothelial electrical

resistance was also maintained for 140 min by S1P+MCDB in cell monolayers
transfected with a scrambled siRNA then administered EGTA (Fig. 4e); VE-cadherin
was localized to intercellular junctions in those cell monolayers (Fig. 4f upper).

In

contrast, treatment with S1P alone, without the addition of MCDB, induced only a
transient increase in electrical resistance, as electrical resistance returned to the EGTAonly treated value by 140 min (Fig. 1a,c), and at that time-point junctional localization of
VE-cadherin was much reduced (Fig. 2b). The activity of S1P was also transient in cell
monolayers pretreated with the VE-cadherin antibody, which was not removed during
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the course of the experiment (data not shown). Furthermore, S1P activity was transient
in those cell monolayers reduced of VE-cadherin protein by gene silencing followed by
chelation of extracellular Ca2+ with EGTA (Fig. 4e). Immunofluorescent staining of VEcadherin was much reduced at intercellular junctions at the end of the experiment in
these cell monolayers (Fig. 4f lower). Therefore, the sustained increase in endothelial
electrical resistance induced by S1P, using the EGTA protocol, appears to require VEcadherin.
S1P induced cell spreading. Imaging of live cells with phase-contrast and DIC
optics revealed that endothelial cells within a monolayer spread following the
administration of S1P (Fig. 5).

Administration of EGTA for 10 min increased the

birefringence, indicative of a change in cell shape, of the cell monolayers as viewed by
phase-contrast optics (Fig. 5a) and caused gaps with connecting strands to form
between cells as viewed with DIC optics (Fig. 5b). Subsequent treatment for 10 min
with S1P alone or in combination with MCDB resulted in cellular changes indicative of
cell spreading, i.e. reduction of the birefringence (Figs. 5a), reduction of the connecting
strands between cells, closure of intercellular gaps (Figs. 5b), appearance of flatter cells
(Figs. 5b), and ridges between adjacent cells (Fig. 5b, EGTA:S1P). Addition of MCDB
alone to restore extracellular Ca2+ caused cell spreading and closure of intercellular
gaps but to a much lesser extent than with S1P. These observations implicate cell
spreading and the resultant closure of intercellular gaps as the mechanism for the S1Pinduced rapid increase in electrical resistance of endothelial cell monolayers.

Latrunculin B inhibited S1P effects on electrical resistance and cell spreading.
S1P is known to reorganize actin filaments to the cell periphery (8). Visualization of
actin filaments with phalloidin conjugated to Alexa Fluor 488 revealed in the present
study that S1P also reorganized actin to the cell periphery in the presence of reduced
VE-cadherin at intercellular junctions, resulting from administration of EGTA (Fig. 2a).
To determine the role of actin in the barrier-enhancing activity of S1P, actin
polymerization was blocked with Latrunculin B. Latrunculin B binds to actin monomers
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Figure 5. S1P induced cell spreading. Cell spreading and closure of intercellular gaps of HUVEC
monolayers were visualized with phase-contrast (a) and differential interference-contrast (DIC, b)
optics. Increased birefringence (a) and gaps (b) with connecting strands between adjacent cells
(b) were induced by 10-min incubation with EGTA (2mM) to culture medium. HUVEC monolayers
were then treated for 10 min with MCDB or S1P alone or S1P+MCDB. Note that S1P treated
without or with MCDB decreased birefringence (a) and induced cells to spread, resulting in
closure of most of the intercellular gaps (b). Same group of cells are depicted in each row in (a)
and (b). Scale bars, a = 2 μm; b = 20 μm.
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Figure 6. Inhibitor of actin polymerization attenuated S1P-induced increase in endothelial
electrical resistance and cell spreading. HUVEC monolayers were pretreated for 30 min
with Latrunculin B (Lat) to inhibit actin polymerization before treatment with S1P for 10 min.
a) Depicts peak increases in electrical resistance, as normalized to basal values (E/B). b)
VE-cadherin and actin were visualized, respectively, by incubation with rabbit anti-human
VE-cadherin polyclonal antibody and Alexa Fluor 488-labeled goat anti-rabbit secondary
antibody and Alexa Fluor 594-labeled phalloidin. Same group of cells are depicted in each
column in (b). c,d) Same group of cells in each row were imaged with phase-contrast (c)
and DIC (d) optics. EGTA was administered to disrupt homophilic VE-cadherin binding,
resulting in formation of intercellular gaps. Note that Latrunculin B attenuated increase in
endothelial electrical resistance (a) and reorganization of filamentous actin (F-actin) to cell
periphery (b), decrease in birefringence of cell monolayers (c), and cell spreading and
closure of intercellular gaps (d) induced by S1P. Latrunculin B did not affect S1P-induced
increase in localization of junctional VE-cadherin (b). n= 5 in each group in (a); *P<0.05 vs.
DMSO+S1P group. Scale bars, b = 10 μm; c = 2 μm; d = 20 μm.
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that results in the inhibition of the actin nucleation during polymerization of actin
filaments. Pre-treatment with Latrunculin B for 30 min attenuated the increase in
endothelial electrical resistance (Fig. 6a) and reorganization of peripheral actin (Fig. 6b)
but had no effect on the increase in junctional VE-cadherin induced by S1P (Fig. 6b).
Latrunculin B also prevented cell spreading induced by S1P. S1P reversed the EGTAinduced increases in birefringence (Fig. 6c) and gap formation (Fig. 6d) in cell
monolayers pretreated with the vehicle, dimethyl sulfoxide (DMSO), but not with
Latrunculin B.
Visualization of actin filaments with phalloidin conjugated to Alexa Fluor 488
revealed in the present study that S1P also reorganized actin to the cell periphery in the
presence of reduced VE-cadherin at intercellular junctions, resulting from administration
of EGTA (Fig. 2a). To determine the role of actin in the barrier-enhancing activity of
S1P, actin polymerization was blocked with Latrunculin B. Latrunculin B binds to actin
monomers that results in the inhibition of the actin nucleation during polymerization of
actin filaments. Pre-treatment with Latrunculin B for 30 min attenuated the increase in
endothelial electrical resistance (Fig. 6a) and reorganization of peripheral actin (Fig. 6b)
but had no effect on the increase in junctional VE-cadherin induced by S1P (Fig. 6b).
Latrunculin B also prevented cell spreading induced by S1P. S1P reversed the EGTAinduced increases in birefringence (Fig. 6c) and gap formation (Fig. 6d) in cell
monolayers pretreated with the vehicle, dimethyl sulfoxide (DMSO), but not with
Latrunculin B.

Rho kinase inhibitor attenuated S1P effects on electrical resistance and cell
spreading. Rho kinase and its downstream effectors influence cofilin, an actin severing
protein (8).

Inhibition of cofilin by activated Rho kinase has been proposed to be

responsible for the reorganization of peripheral actin induced by S1P (8). Pre-treatment
for 30 min with 5 μM Y-27632, a pharmacological inhibitor of Rho kinase, decreased
basal endothelial electrical resistance and significantly attenuated the rapid increase in
electrical resistance induced by S1P when administered either under normal conditions
(Fig. 7a) or after EGTA treatment (Fig. 7b); Y-27632 at 1 μM had no effect in either
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Figure 7. Inhibitor of Rho kinase attenuated S1P-induced increase in endothelial electrical
resistance and cell spreading. HUVEC monolayers were pretreated for 30 min with Y-27632
(Y, 1 and 5 μM), an inhibitor of Rho kinase, before treatment with S1P (a,c,d), MCDB alone
(b), or S1P+MCDB (b) . a) Depicts peak increases in electrical resistance, as normalized to
basal values (E/B). b,c,d) EGTA was added to disrupt homophilic VE-cadherin binding and
induce formation of intercellular gaps. Same group of cells in each row were imaged with
phase-contrast (c) or DIC (d) optics. Note that Y-27632 at 5 μM attenuated increase in
endothelial electrical resistance (a,b), decrease in birefringence of cell monolayers (c), and
cell spreading and closure of intercellular gaps (d) induced by S1P. Y-27632 at 1 μM had no
effect on these parameters. n=3 in each group in (a) and n=4 in each group in (b); *P<0.05
vs. Control (Con)+S1P group (a) and Y, 1 μM+EGTA:MCDB+S1P (b). Scale bars, c = 2 μm;
d = 20 μm.
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condition (Fig. 7a,b). In the EGTA protocol, addition of MCDB caused a small increase
in endothelial electrical resistance, which slowly increased to the pre-control level (Fig.
7b), an observation similar to that depicted in Fig. 1a. Pre-treatment with Y-27632
before the addition of EGTA also attenuated the decrease in birefringence, spreading of
endothelial cells, and closure of intercellular gaps induced by S1P, as viewed by phasecontrast (Fig. 7c) and DIC (Fig. 7d) optics. Therefore, the findings with inhibitors of
actin polymerizaton and Rho kinase suggest that S1P rapidly increases endothelial
electrical resistance via an actin-dependent process that involves Rho kinase.
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DISCUSSION
Two publications have demonstrated that S1P enhances the localization of
endothelial adherens junction proteins, VE-cadherin and catenins, within 30 to 60 min of
treatment (9, 13). S1P, however, rapidly increases endothelial barrier function (8, 17),
as noted by a peak increase in electrical resistance within 6-10 min. Whether VEcadherin plays a significant role in this rapid activity of S1P was an intriguing question
especially after I observed that S1P enhanced the localization of VE-cadherin within 10
min of treatment. Based on experiments whereby homophilic VE-cadherin binding was
disrupted by three different mechanisms, cell monolayers were imaged with phasecontrast and DIC optics, and inhibitors of actin polymerization and Rho kinase were
administered, I conclude that the rapid increase in endothelial electrical resistance
induced by S1P occurs independently of homophilic VE-cadherin binding and requires
cell spreading and Rho kinase. However, our initial findings suggest that the sustained
activity of S1P, demonstrated in the EGTA protocol, requires VE-cadherin.
S1P induces the assembly of adherens junctions via activation of the small
GTPases, Rac1 and Rho (9, 13). Localization of VE-cadherin and the catenins, α, β,
and γ, to intercellular junctions increased markedly and more VE-cadherin was
demonstrated in the Triton X-100 insoluble (actin associated fraction) within 60 min in
HUVECs treated with S1P. Either inhibition of Rho with C3 exoenzyme or Rac1 with
dominant-negative N17Rac1 diminished the increased immunofluorescent staining of
VE-cadherin at intercellular junctions (9).

Similar increases in VE-cadherin and β-

catenin were also observed at intercellular junctions within 30 min of treatment of S1P
(13). In the present study, I observed an increased immunofluorescent localization of
VE-cadherin at intercellular junctions within 10 min of S1P treatment.
Since this 10-min time point temporally aligns with the rapid activity of S1P, I
determined if VE-cadherin is responsible for the rapid increase in endothelial electrical
resistance induced by S1P. Homophilic VE-cadherin binding was disrupted by three
different protocols, and all three protocols caused the reduction in immunofluorescent
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localization of VE-cadherin at intercellular junctions, separation of adjacent endothelial
cells, and a decrease in basal, endothelial electrical resistance. The important finding
was that S1P rapidly increased endothelial electrical resistance in all three protocols.
Following the administration of EGTA, the rapid increase in electrical resistance
occurred when S1P was administered either without or with restoration of extracellular
Ca2+ with MCDB.

VE-cadherin was present at intercellular junctions in monolayers

treated with MCDB alone and was increased with treatment of S1P plus MCDB, but
there was much less VE-cadherin observed at intercellular junctions following treatment
with S1P alone. S1P was also effective in increasing endothelial electrical resistance
after presumably interfering with homophilic VE-cadherin binding by incubation with an
antibody to the extracellular domain of VE-cadherin or after VE-cadherin was reduced
significantly by gene silencing. These findings support our conclusion that S1P rapidly
increases endothelial electrical resistance independently of homophilic VE-cadherin
binding.
The sustained increase in electrical resistance induced by S1P appears to
require extracellular Ca2+ and the localization of VE-cadherin at intercellular junctions.
Following the administration of EGTA, the increased electrical resistance induced by
S1P was sustained in cell monolayers containing junctional VE-cadherin. After EGTA,
the sustained increase in electrical resistance induced by S1P required restoration of
extracellular Ca2+ with MCDB, which was associated with the presence of VE-cadherin
at intercellular junctions.

Similarly, S1P maintained electrical resistance in cell

monolayers containing junctional VE-cadherin after transfection with scrambled siRNA
and the subsequent administration of EGTA. In contrast, treatment with S1P without
replenishment of extracellular Ca2+ following EGTA or after reduction of VE-protein
coupled with EGTA resulted in only a transient increase in electrical resistance, and
junctional VE-cadherin was much reduced at the 140-min time point.
I next determined if S1P induced cell spreading, because in the initial
experiments S1P reorganized actin to the cell periphery and also appeared to reduce
the width of intercellular gaps initially formed by EGTA. Cell spreading is also induced

34

by cAMP-enhancing agents that are well known to rapidly tighten the endothelial barrier
in association with reorganization of actin to the cell periphery (15, 22). S1P has been
shown to induce membrane ruffling and cell spreading in single endothelial cells of
human umbilical origin and to increase cell size (6, 18). S1P also formed lamellipodia
and induced cell spreading of endothelial cells at the leading edge of wounded, HUVEC
monolayers resulting in closure of the wound (25). In the present study, I observed by
imaging with phase-contrast and DIC optics that S1P also induces spreading of
endothelial cells grown as confluent monolayers.

Treatment for 10 min with S1P

2+

caused cells to spread resulting in

without or with MCDB to restore extracellular Ca

closure of intercellular gaps, initially formed by EGTA. These observations indicate that
the rapid increase in electrical resistance across endothelial cell monolayers induced by
S1P occurs via cell spreading and the subsequent closure of intercellular gaps.
Although the above-mentioned formation of lamellipodia and subsequent closure of
wounded HUVEC monolayers implicates the process of cell spreading, the conditions
(injury versus EGTA-induced gap formation) and the signaling pathways are different.
Wound closure by S1P was prevented by pre-treatment with inhibitors of Src (PP2) and
mitogen-activated protein kinase (U0126); whereas, the increased endothelial electrical
resistance induced by S1P was not affected by PP2 or U0126 (8). Similarly, it was
shown previously that U0126 did not block the increase in endothelial electrical
resistance induced by platelet-conditioned medium (7), of which S1P has been
suggested as the barrier-enhancing factor (20).
Garcia et al. (8) initially demonstrated that S1P remodeled actin to the cell
periphery and that Latrunculin B, an inhibitor of actin polymerization, or Y-27632, an
inhibitor of Rho kinase, attenuated the S1P-induced increase in endothelial electrical
resistance.

I confirmed these findings and, in addition, demonstrated that S1P

reorganized actin to the cell periphery following disruption of homophilic VE-cadherin
binding with EGTA and that pretreatment with Latrunculin B or Y-27632 (5 μM)
attenuated actin reorganization and the cell spreading induced by S1P. Y-27632 also
lowered basal, endothelial electrical resistance in HUVEC monolayers.

The

preventative effects of Y-27632 may be explained by the ability of Rho kinase to
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inactivate cofilin, an actin-severing protein, via the phosphorylation of LIM kinase.
Expression of wild-type cofilin has been reported to reduce the S1P-induced increases
in peripheral actin and in endothelial electrical resistance (8). Rho kinase is also an
effector for the small GTPase Rho, and activation of Rho has been implicated in the
spreading of single endothelial cells by S1P (18) or of cells grown on type IV collagen
(10). In these studies, inactivation of Rho with C3 exoenzyme blocked spreading of
endothelial cells.

The barrier-enhancing activity of S1P, therefore, appears to be

dependent on the Rho-Rho kinase-signaling pathway.
Rho kinase has also been implicated in loosening of the endothelial barrier. Y27632 attenuated the activated neutrophil-induced increases in albumin permeability of
porcine coronary venules and of cell monolayers derived from coronary venular
endothelia and in cell tension of coronary venular endothelia (2). A similar attenuation
of albumin permeability by Y-27632 was demonstrated in porcine coronary venules and
coronary venular endothelia treated with vascular endothelial growth factor (23).
Furthermore, transfection of constitutively active Rho kinase increased the permeability
and endothelial cell tension in these two model systems (2). With regard to the effect of
inhibition of Rho kinase on thrombin’s ability to increase endothelial permeability, the
findings are equivocal. In one study, Y-27632 prevented the increase in endothelial
permeability (27), but not in another study (3). Y-27632 per se enhanced the barrier
function of cell monolayers derived from bovine pulmonary artery endothelial cells, as
assessed by a size-selective permeability assay (3). In contrast, I show herein that Y27632 decreased the endothelial barrier function of HUVEC monolayers, as assessed
by a decrease in endothelial electrical resistance.

From the findings of the above

studies and the present study, it is apparent that the outcome of activation of the Rho
kinase-signaling pathway is varied.

One possibility is that the cellular targets

downstream of Rho kinase are different for various mediators or for different cell types
and that separate or parallel pathways differentially influence endothelial barrier
function.
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Study 2

Sphingosine 1-phosphate regulates membrane trafficking of
VE-cadherin: decreasing endocytosis and increasing recycling of
VE-cadherin

Keywords: S1P, Rab11, vascular endothelial growth factor, β-arrestin2,
microscopy, electric cell-substrate impedance sensing, human umbilical
vein endothelial cell, microtubule.
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ABSTRACT
The biologically active lipid, sphingosine 1-phosphate (S1P), induces a myriad of
cellular events including enhancement of the endothelial barrier and an increase in
vascular endothelial (VE) cadherin. Based on the latter observation, I hypothesized that
S1P affects the trafficking of VE-cadherin between cell surface and cytoplasmic
vesicles. Immunofluorescence microscopy and a biotinylated cell impermeable reagent
were used to demonstrate internalized and cell surface VE-cadherin. Endocytosis of
VE-cadherin was induced by EGTA or VEGF. S1P decreased EGTA-induced
endocytosis and co-localization of internalized VE-cadherin with EEA 1, a marker of
early endosomes, and prevented and reversed the effect of VEGF. S1P also increased
the recovery of cell surface VE-cadherin after endocytosis by EGTA or VEGF and
increased the co-localization of internalized VE-cadherin with Rab11, a marker of the
recycling endosome. Bafilomycin A1, an inhibitor of recycling, and microtubule
inhibitors, taxol and colchicine, blocked the increase in junctional VE-cadherin and the
sustained increase in endothelial electrical resistance induced by S1P, the latter using
the Ca2+-switch protocol. Bafilomycin A1 also prevented the increase in recovery of cell
surface VE-cadherin induced by S1P. When co-treated or post-treated with VEGF, S1P
blocked or reversed the increased interaction of VE-cadherin with β-arrestin2, an
endocytic adapter protein. I conclude that S1P stabilizes homophilic VE-cadherin
binding by decreasing endocytosis and increasing recycling of VE-cadherin, the latter
requiring microtubules.
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INTRODUCTION
VE-cadherin, the major protein at endothelial adherens junctions, forms Ca2+dependent homophilic adhesions between cells and is vital to the integrity of the
endothelial barrier. A blocking antibody to VE-cadherin increased the vascular
permeability in heart and lungs of mice (8), and antibodies directed to specific domains
of the extracellular region of VE-cadherin increased the permeability of endothelial cell
monolayers (7, 9) and/or prevented angiogenesis (21). Down-regulation of VE-cadherin
initiates the transition from a normal endothelial phenotype to a mesenchymal
phenotype as is seen in mature bovine systemic and pulmonary endothelial cells and is
related to atherogenesis (2, 3, 13). Induction of endocytosis of VE-cadherin by vascular
endothelial growth factor (VEGF) has been hypothesized as the cellular mechanism for
the VEGF-induced increase in vascular permeability (15). Therefore, alterations in the
level of VE-cadherin have important consequences in endothelial function and
pathophysiology.
Sphingosine 1-phosphate (S1P), released mainly from activated platelets and unstimulated erythrocytes, induces a myriad of cellular events, one of which is
enhancement of the endothelial barrier (14, 27).

S1P rapidly increases endothelial

barrier function as assessed by a peak increase in endothelial electrical resistance
within 6-10 min of treatment (14, 45), prevents the transient increase in hydraulic
conductivity induced by platelet-activating factor in individually perfused microvessels of
the rat mesentery (29), and reduces the increase in pulmonary edema in mice and dogs
subjected to intratracheal endotoxin (26, 34). S1P also enhances the localization of VEcadherin at endothelial junctions and induces the assembly of endothelial adherens
junctions within 10 min of treatment (45). This observation of an increase in junctional
VE-cadherin prompted us to explore the cellular mechanisms for the apparent S1Pinduced stabilization of VE-cadherin.
Gene expression, decreased degradation, and or membrane stabilization could
explain the increased junctional localization of VE-cadherin induced by S1P. Since S1P
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increases junctional VE-cadherin within 10 min, stabilization of membrane trafficking of
VE-cadherin appeared most likely. VE-cadherin constitutively undergoes endocytosis
via a clathrin-dependent pathway (42) and is degraded via a lysosomal pathway (41,
42). Furthermore, trafficking of VE-cadherin has been postulated to be involved in
angiogenesis and regulation of endothelial barrier function (42, 43). VEGF, formerly
known as vascular permeability factor, was recently shown to increase the endocytosis
of VE-cadherin by a signaling pathway involving an enhanced interaction of VEcadherin with β-arrestin2, an endocytic adaptor protein involved in receptor
internalization (15). Trafficking of epithelial (E)-cadherin has been extensively studied
by Stow and co-workers (4, 5, 19, 20). These authors demonstrated that E-cadherin
constitutively traffics from the cell surface to endocytic vesicles and either back to the
surface or to late endosomes to be degraded. However, recycling of E-cadherin to the
cell surface predominates over degradation, promoting stabilization of the barrier (4,
20). Further, endocytosis of E-cadherin is required for signals of fibroblast growth factor
(FGF) receptors (FGFRs) (5).
In this study, I hypothesized that S1P stabilizes VE-cadherin at intercellular
junctions by influencing the trafficking of VE-cadherin, i.e. by decreasing the
endocytosis and increasing the recycling of VE-cadherin. Endocytosis of VE-cadherin
was

induced

by

EGTA

and

physiologically

by

VEGF

and

assessed

by

immunofluorescence microscopy and a biotinylated impermeable reagent. Recovery of
cell surface VE-cadherin or recycling was assessed by the biotinylated reagent, colocalization of VE-cadherin with Rab11, a recycling endosomal marker, and bafilomycin
A1, an inhibitor of recycling endosomes. The interaction of β-arrestin2 with VE-cadherin
was identified by co-immunoprecipitation.

Because active trafficking of intracellular

vesicles involves microtubules (22, 44), inhibitors of microtubules were used to test the
affect of VE-cadherin trafficking induced by S1P.
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MATERIALS AND METHODS

Materials.

S1P was purchased from Avanti Polar Lipids (Alabaster, AL).

Bovine

pulmonary artery endothelial cells were purchased from Vec Technologies, Inc.
(Rensselaer, NY). Gentamicin sulfate was from ICN Biomedicals, Inc. (Aurora, OH).
Newborn calf serum and bovine brain extract were from Cambrex Corporation (East
Rutherford, NJ). Sulfosuccinimidyl 2-(biotinamido) ethyl-dithioproprionate (sulfo-NHSSS-biotin) was purchased from Pierce (Rockford, IL). Recombinant human VEGF 165
was purchased from R&D systems, Inc. (Minneapolis, MN). Prolong Gold anti-fade
reagent and Alexa Fluor-labeled secondary antibodies were from Invitrogen Molecular
Probes (Eugene, OR).

Gold-coated electrodes for the measurement of electrical

resistance by Electrical Cell-Substrate Impedance Sensing (ECIS) were from Applied
Biophysics (Troy, NY).

VE-cadherin antibodies were purchased from Axxora (San

Diego, CA) and Beckman Coulter Company (Marseille Cedex, France).

β-arrestin2

antibody was purchased from Novus Biologicals (Littleton, CO). β-catenin antibody was
from BD Bioscience (San Jose, CA). p120-catenin antibody and protein A/G beads
were from Santa Cruz Biotechnology (San Diego, CA).

Horseradish peroxidase

conjugated secondary antibodies were purchased from Chemicon International
(Temecula, CA). Nitrocellulose membranes and ECL (enhanced chemiluminescence)
Western blotting detection reagents were purchased from Amersham Biosciences
(Buckinghamshire, England).

Bafilomycin A1 was purchased from LC Laboratories

(Woburn, MA). Cycloheximide was a gift from Dr. Chuan Hu. All other chemicals were
from Sigma-Aldrich (St. Louis, MO).
Cell culture. Human umbilical vein endothelial cells (HUVEC) were isolated from fresh
human placentas by 1 mg/ml of type I collagenase and grown in MCDB-131 (MCDB)
culture medium containing 5% (v/v) human serum, 20% (v/v) newborn calf serum, 7.5
μg/ml of endothelial cell growth supplement, 4.5 μg/ml of bovine brain extract, 25 μg/ml
of porcine intestinal heparin, and 50 μg/ml of gentamicin sulfate at 37°C in 5% CO2.
HUVECs were used between passages 2 and 8.

Before treatments or ECIS

experiments, HUVEC monolayers were serum-starved for 2 h. Bovine pulmonary artery
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endothelial cells (BPAEC, passages 3-18) were cultured in MCDB medium containing
10% fetal bovine serum and 50 μg/ml of gentamicin sulfate. BPAEC monolayers were
serum-starved for 4 h before treatments.

HUVECs were used for all experiments

except for experiments with VEGF.
Transendothelial electrical resistance. Electrical resistance across HUVEC and BPAEC
monolayers was measured continuously with ECIS to assess changes in endothelial
barrier function.

Briefly, cells were seeded onto ECIS cultureware (0.8 cm2/well)

precoated with 0.2% gelatin. The measured electrical resistance was of those cells
located on the small gold electrode (5 x 10

4

cm2) in each of the wells. The culture

medium was the electrolyte, and the small gold electrode, covered by confluent
endothelial cells, and a larger gold counter-electrode (~2 cm2) were connected to a
phase-sensitive, lock-in amplifier. A constant current of 1 μA was supplied by a 1-V,
4000-Hz alternating current through a 1-MΩ resistor.

The computer controlled the

output of the amplifier and switched the measurements to different electrodes in each of
two 8-well arrays during the course of an experiment. Changes in voltage between the
small electrode and the large counter electrode were monitored by the lock-in amplifier,
stored, and then calculated as impedance by the computer. Data are presented as
changes in the resistive portion of electrical impedance normalized to the initial value at
time 0.
Ca2+-switch protocol. Cell monolayers were treated with 2 mM EGTA (ethylene glycolbis(2-amino-ethylether)-N,N,N’,N’-tetra-acetic acid) for 10 min to chelate extracellular
Ca2+, followed by (1) adding nothing, (2) adding fresh MCDB containing 1.6 mM Ca2+ to
restore extracellular Ca2+, or (3) adding 1 μM S1P and fresh MCDB.
Immunofluorescence microscopy. After treatments, cell monolayers were rinsed quickly
with phosphate-buffered saline containing Ca2+ and Mg2+ (PBS+/+). Cells were fixed,
permeabilized, and incubated with 5% BSA. Cells were then incubated with primary
antibodies, followed by Alexa Fluor-labeled secondary antibodies, and rinsed several
times with PBS+/+. Cells were mounted with Prolong Gold anti-fade reagent. Images
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were generated by confocal laser scanning with a Zeiss LSM 510 confocal microscope.
For the same group of images, the fluorescent signals were measured at emission
wavelengths of 488 and 594 nm with the same pinhole (less than 1 μm), the same
detector gain, and the same amplifier offset.
To better visualize internalized VE-cadherin, cell surface (antibody labeled) VEcadherin was removed with an acid wash. Briefly, BPAECs were pre-incubated for 1 h
with serum-free MCDB containing 20 mM HEPES, a mouse anti-human VE-cadherin
antibody (cad5; 1:50 dilution) against its extracellular domain, and 3% BSA at 4°C,
followed by several washes in PBS+/+ to remove extra antibody, and then cultured with
MCDB for 30 min at 37°C in 5% CO2. After indicated treatments, BPAECS were
separated into two groups, one group was administered a mild acid wash (PBS, pH 2.7,
containing 25 mM glycine and 3% BSA) for 15 min at 4°C to remove cell surface bound
antibody while retaining internalized antibody (16, 43), whereas the other group was
washed with PBS. The cells were then processed for immunofluorescence microscopy.
Transfection. Enhanced GFP (EGFP)-tagged Rab11 was transfected into HUVECs by
electroporation with the Nucleofector I device (Amaxa Biosystems, Berlin, Germany).
Briefly, 90% confluent HUVEC monolayers were trypsinized and counted.

After

centrifugation, 1.0x106 cells were resuspended in 100 μl of Nucleofector solution (7.25
mM ATP, 12 mM MgCl2 ⋅ 6H2O, 88 mM KH2PO4, 14 mM NaHCO3, and 2 mM glucose at
pH 7.4) with EGFP-tagged Rab11 and transferred immediately to a cuvette and
electroporated in the Nucleofector apparatus, using program U-001. Transfected cells
were recovered with fresh medium at 37°C for 5 min and seeded on gelatin-coated
glass cover-slips. Cells were placed in a humidified environment and maintained at
37°C and 5% CO2 for 2 d until used for experimentation.
Immunoblotting. Cells were washed 2x in ice-cold PBS, lysed in RIPA buffer (15 mM
NaCl, 50 mM Tris, 1% NP-40, 0.5% sodium deoxycholate) containing 2 mM EGTA, 1
mM sodium vanadate, 1 mM phenylmethanesulfonyl fluoride (PMSF), 5 μg/ml of
aprotinin, and 2 μg/ml of leupeptin. Samples were clarified by centrifugation at 14,000
rpm for 10 min at 4°C. Proteins were resolved by sodium dodecyl sulfate47

polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to Nitrocellulose
membrane using a mini-Protean electrophoresis system. Protein blots were probed
with indicated primary antibodies, followed by the appropriate horseradish peroxidaseconjugated secondary antibody, and developed by enhanced chemiluminescence.

Biotinylation assay for assessment of VE-cadherin trafficking.

Internalized and cell

surface VE-cadherin were quantified by using a biotinylation assay (5, 20). Cell surface
proteins were covalently labeled with 1.0 mg/ml of sulfosuccinimidyl 2-(biotinamido)
ethyl-dithioproprionate (sulfo-NHS-SS-biotin), a biotin-labeled cell impermeable reagent.
Assessment of internalized VE-cadherin (endocytosis). Cell monolayers were
incubated with sulfo-NHS-SS-biotin at 0°C for 1 h followed by washing with a blocking
reagent for sulfo-NHS-SS-biotin at 4°C for 10 min to quench free sulfo-NHS-SS-biotin.
Cells were cultured in MCDB at 37°C for 30 min and treated with S1P. Endocytosis was
stimulated by increasing temperature to 37°C, by lowering extracellular Ca2+ with EGTA,
or by treatment with VEGF (15). After endocytosis, cell monolayers were washed 2x for
20 min each with a glutathione solution at 4°C to remove cell surface biotin.
Internalized biotinylated proteins were protected from glutathione stripping. Cells were
lysed in RIPA buffer with protease inhibitors. Equal amount of proteins was incubated
with streptavidin beads and resolved by SDS-PAGE. Internalized, biotinylated VEcadherin was identified with an anti-VE-cadherin antibody to the extracellular domain.
Assessment of cell surface VE-cadherin. Endocytosis was induced by EGTA,
and cells were treated with VEGF or S1P, then incubated at 0°C with the biotin-labeled
cell impermeable reagent. Cell lysates were processed as described above and
assessed only for cell surface, actually recovered cell surface, VE-cadherin.

Co-immunoprecipitation.

Cells were lysed in RIPA buffer with phosphatase and

protease inhibitors, and lysates were centrifuged at 14,000 rpm for 10 min at 4°C to
clear debris.

About 2 mg of protein was incubated with a rabbit anti-human VE-

cadherin antibody for 2 h at 4°C after preclearing with 50 μl of protein A/G beads for 1 h.
Protein A/G beads were added and incubated for additional hour to pull down antibody-
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bound proteins. Beads were washed with RIPA buffer several times and boiled in 3x
sample buffer. Proteins were resolved and analyzed by Western blotting.
Statistics. All values are means ± SE. A minimum of six experiments was conducted
for ECIS experiments and three experiments for the biotinylation assay and microscopy.
Data on electrical resistance were analyzed with a 2-way analysis of variance with
repeated measures (40). Statistical significance was set at P<0.05.
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RESULTS
S1P increased junctional localization of VE-cadherin and p120. Within 10 min of
treatment, 1 μM S1P increased the immunofluorescent staining of VE-cadherin and
p120 at intercellular junctions (Fig. 1). S1P also increased N-cadherin at intercellular
junctions (data not shown) but did not appear to affect junctional β-catenin.

This

increase in junctional VE-cadherin was also observed using the Ca2+-switch protocol
(Fig. 2a), whereby Ca2+ dependent, homophilic VE-cadherin binding was disrupted with
addition of EGTA, then restored with addition of fresh MCDB. Administration of EGTA
resulted in a loss of VE-cadherin at cell-cell contacts and an increase in cytoplasmic
vesicles stained for VE-cadherin. Upon restoration of extracellular Ca2+ with MCDB,
VE-cadherin was present at intercellular junctions by 10 min, but to a greater extent
when also treated with S1P+MCDB (Fig. 2a).

Figure 1. Sphingosine 1-phosphate (S1P) increased VE-cadherin and p120 at cell-cell
contacts. Endothelial cell monolayers derived from human umbilical veins (HUVEC)
and seeded on glass coverslips were treated with S1P (1 μM) for 10 min. VE-cadherin
was visualized by incubation with a mouse anti-human VE-cadherin primary antibody
(Cad 5) and an Alexa Fluor 594-labeled goat anti-mouse secondary antibody. p120
and β-catenin were viewed, respectively, by a polyclonal or monoclonal antibody.
Column 3 depicts the merged image of VE-cadherin and p120. Scale bar, 20 μm.
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Figure 2. S1P influenced trafficking of VE-cadherin. Endocytosis of VE-cadherin in HUVEC
monolayers was induced by EGTA (2 mM, a) or by increasing temperature (e). a) VE-cadherin
was visualized by incubation with a rabbit anti-human antibody against the extracellular domain
followed by Alexa Fluor488-labeled secondary antibody. b) Recovery of cell surface VEcadherin. HUVEC monolayers were incubated with EGTA for 10 min at 37°C to induce
endocytosis followed by an additional 10 min of EGTA (post-treatment control group) or
treatment with MCDB or S1P+MCDB for an additional 10 min. Cells were then incubated at 0°C
with cell impermeable marker, sulfo-NHS-SS-biotin, for 1 h. Cell lysed in RIPA buffer with
protease inhibitors, and equal amount of protein was incubated with streptavidin beads to
complex biotin-labeled proteins. Proteins were resolved on SDS-PAGE and VE-cadherin
identified with a rabbit anti-human antibody against its extracellular domain. VE-cadherin in total
cell lysate was used as loading control. c) Cells were pre-incubated at 0°C with sulfo-NHS-SSbiotin, administered EGTA at 37°C, then treated as described in (b). Cell surface biotin-labeled
proteins were removed by two, 20 min washed with glutathione at 0°C, leaving internalized
biotinylated proteins resistant to glutathione. Cell lysates were processed as decribed in (b). d)
Quantification of three immunoblots shown as ratio of individually treated group to control group.
e) Cells were incubated at 0°C with sulfo-NHS-SS-biotin for 1 h, and then temperature was
increased from 0°C to 37°C and treated with S1P. Cell lysates were processed as described in
(b). b,c,d) Note that S1P decreased endocytosis and increased recovery of VE-cadherin in
comparison with MCDB. *P < 0.05 vs. MCDB group, #P < 0.05 vs. EGTA groups. Scale bar, 10
µm.
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S1P decreased endocytosis of VE-cadherin and increased recovery of cell
surface VE-cadherin. Internalized and cell surface VE-cadherin were visualized by
immunofluorescence microscopy and quantified by the biotinylation assay. Addition of
EGTA for 10 and 20 min (the latter used as the control group for post-treatments)
induced the endocytosis of VE-cadherin (Fig. 2a, c, d). Post-treatment with MCDB for
10 min reduced the amount of internalized VE-cadherin.

Post-treatment with S1P

further decreased the immunofluorescent localization of VE-cadherin in the cytoplasm
(Fig. 2a) and significantly reduced the amount of internalized, biotin-labeled VEcadherin in comparison with the EGTA- and MCDB-treated groups (Fig. 2, c and d,
internalized).

Endocytosis was also induced by increasing temperature from 0°C,

temperature at which cell surface proteins were labeled with sulfo-NHS-SS-biotin, to
37°C. S1P decreased the temperature-induced endocytosis of VE-cadherin at 10 and
30 min of treatment (Fig. 2e). Opposite results were obtained for the recovery of cell
surface VE-cadherin. Administration of EGTA dramatically decreased cell surface VEcadherin in the initial 10-min and post-10-min treatment (Fig. 2, b and d, cell surface).
Post-treatment for 10 min with MCDB slightly increased cell surface VE-cadherin;
whereas, S1P significantly increased the amount of cell surface VE-cadherin as viewed
by immunofluorescent staining (Fig. 2a) and quantification by the biotin assay (Fig. 2,b
and d, cell surface).

Quantification of three immunoblots depicts the statistically

significant effects of S1P on endocytosis and recovery of cell surface VE-cadherin using
the biotinylation assay (Fig. 2d). These results demonstrate that S1P influences VEcadherin trafficking.

S1P decreased and reversed VEGF effects on endothelial electrical resistance,
VE-cadherin trafficking, and interaction with β-arrestin2. Next, it was determined if S1P
could affect the trafficking of VE-cadherin by the physiologically relevant mediator,
VEGF (15). For these experiments, it was necessary to switch to BPAEC monolayers,
because VEGF mimicked the effects of S1P on increasing endothelial electrical
resistance and decreasing the endocytosis of VE-cadherin in HUVEC monolayers. In
BPAEC monolayers, S1P prevented and reversed the decrease in endothelial electrical
resistance induced by VEGF (Fig. 3a). The effect of VEGF on internalization of VE-
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cadherin was viewed by immunofluorescence microscopy (Fig. 3b) and quantified by
the biotinylation assay (Figs. 3, c and d).

Immunofluorescent localization of VE-

cadherin at intercellular junctions was observed by incubation with an antibody to the Nterminus of VE-cadherin.

VEGF decreased the junctional staining of VE-cadherin and

increased the number of endocytic vesicles containing VE-cadherin (Fig. 3b, top row).
Co-treatment of S1P+VEGF blocked the VEGF effect resulting in the maintenance of
cell-surface VE-cadherin (Fig. 3b, top row). An acid wash was applied to remove all cell
surface antibodies enabling identification only of acid-resistant, internalized VE-cadherin
(Fig. 3b, bottom row). This technique revealed a lesser amount of internalized VEcadherin in the cell monolayers co-treated with VEGF+S1P versus treatment with VEGF
alone. Using the biotinylation assay, it was demonstrated that VEGF increased the
internalization of VE-cadherin (Fig. 3, c and d, internalized) and much less biotinylated
VE-cadherin was recovered at the cell surface (Fig. 3, c and d, cell surface). S1P
induced the opposite effects. Furthermore, S1P prevented and reversed these effects
of VEGF when co-treated or post-treated for 30 min following the initial 30-min
treatment with VEGF. These data demonstrate that S1P can block the VEGF-induced
endocytosis of VE-cadherin.
It was previously demonstrated that the increased endocytosis of VE-cadherin
induced by VEGF requires an enhanced interaction of β-arrestin2 with VE-cadherin
(15). I confirmed this finding in BPAEC monolayers and extended this finding to show
that S1P induced the opposite effect within 30 min of treatment (Fig 3, e and f).
Furthermore, both co-treatment and post-treatment with S1P decreased and reversed
the VEGF-induced interaction of β-arrestin2 with VE-cadherin.
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Figure 3. S1P decreased and reversed effects of VEGF. Endothelial cell monolayers
derived from bovine pulmonary arteries (BPAEC) were treated individually with S1P or
VEGF or in combination or pretreated for 30 min with VEGF then post-treated for 30 min
with S1P. a) Cell monolayers (n=5) were monitored continuously for changes in endothelial
electrical resistance. b) Cell monolayers were pre-incubated with a monoclonal VEcadherin antibody (cad 5) against its extracellular domain at 4°C for 1h following treatments
at 37°C. Cells were either washed with mild acid to remove VE-cadherin antibody to better
visualize internalized VE-cadherin (second row) or not washed to view cell surface and
internalized VE-cadherin antibody, and then processed for immunofluorescent staining of
VE-cadherin.
c) Cells were incubated with sulfo-NIH-SS-biotin for assessment of
internalized and cell surface VE-cadherin (see Fig. 2 and Methods for details). VE-cadherin
in total cell lysate was used as loading control. d) Quantification of three immunoblots
shown as a ratio of individually treated group to control group. e) Interaction of VE-cadherin
with β-arrestin2. Cell lysates were immunoprecipitated with a rabbit anti-human VEcadherin antibody and immunoblotted for β-arrestin2 and VE-cadherin. (f) Quantification of
three immunoblots as normalized to VE-cadherin blots. Note that S1P opposed these
effects of VEGF and also blocked and reversed effects of VEGF when co- or post-treated.
*P < 0.05 vs. VEGF groups. Scale bar, 10 μm.

54

S1P increased co-localization of Rab11 with VE-cadherin.

Exocytosis (or

recycling) also contributes to trafficking. Therefore, it was determined if VE-cadherin is

Figure 4. S1P increased co-localization of Rab11 with VE-cadherin. Enhanced green
fluorescent protein (EGFP) tagged Rab11, a marker of recycling endosomes, was
transiently transfected by electroporation into HUVECs. After 48 h, endocytosis was
induced with EGTA followed by treatment with S1P+MCDB or MCDB alone. VE-cadherin
was visualized by incubation with monoclonal antibody (Cad 5) and Alexa Fluor 594labeled secondary antibody. Note that VE-cadherin co-localized with EGFP-Rab11
prominently in perinuclear recycling endosome (columns 2, 3, and 5) and also co-localized
adjacent to the plasma membrane (columns 3 and 4) after treatment with S1P. Scale bar,
5 μm.

associated with Rab11, a marker of recycling endosomes. EGFP-tagged Rab11 was
transiently transfected by electroporation into HUVECs, and cells were visualized by
immunofluorescence microscopy during the Ca2+-switch protocol. Figure 4 shows that
the expressed EGFP-Rab11 distributed throughout the cell but localized primarily in an
area that could be considered the perinuclear, recycling endosome (top row).

VE-

cadherin localized at cell junctions in the control setting and after treatment with S1P for

55

10 min (columns 1 and 4). As expected, administration of EGTA for 10 min triggered
the internalization of VE-cadherin, that was observed throughout the cell but
predominantly in the perinuclear, recycling endosome where VE-cadherin was colocalized with Rab11 (merge row, columns 2, 3 and 5). After treatment with S1P for 5
min, VE-cadherin remained co-localized with Rab11 in the perinuclear, recycling
endosome but was also distributed with Rab11 adjacent to the plasma membrane
(column 3). Upon treatment with S1P for 10 min, less VE-cadherin was co-localized
with Rab11 in the recycling endosome and at the cell surface, and VE-cadherin once
again outlined the cell (column 4). With MCDB treatment, VE-cadherin co-localized with
Rab11 only in the perinuclear, recycling endosome (column 5).
S1P increased recycling of VE-cadherin. Dependency on a recycling pathway for
the S1P-induced increase in junctional localization of VE-cadherin demonstrated in
Figure 1 was further demonstrated using the recycling inhibitor, bafilomycin A1.
Bafilomycin A1 blocks the ATP-dependent proton pump that results in the inhibition of
acidification of endosomes (20). It has been suggested that endosome acidification
plays a crucial role in the recycling of internalized vesicles back to the plasma
membrane. Pre-treatment with 1 μM bafilomycin A1 for 1 h prevented the S1P-induced
increase in junctional VE-cadherin (Fig. 5a). Bafilomycin A1 also blocked (Fig. 5b,
lanes 5 and 6, and c) the S1P-induced increase in biotin-labeled, cell surface VEcadherin at 10 and 60 min (Fig. 5 b, lanes 2 and 3, and c) as assessed by the
biotinylation assay. S1P also increased biotin-labeled, cell surface p120 at 10 and 60
min (Fig. 5b, lanes 2 and 3, and d); however, bafilomycin A1 did not inhibit the S1Pinduced increase in cell surface p120 at 10 and 60 min (Fig. 5b, lanes 5 and 6, and d).
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Figure 5. S1P augmented recycling of VE-cadherin. HUVEC monolayers were pretreated
for 60 min with bafilomycin A1 (1 μM), dissolved in dimethyl sulfoxide (DMSO), to inhibit
recycling of VE-cadherin.
Cell surface VE-cadherin was identified either by
immunofluorescence microscopy (a) or by immunoprecipitation of biotin-labeled proteins
with streptavidin beads and immunoblotting with VE-cadherin (b). The latter method was
also used to identify cell surface p120 (b). c,d) Quantification of three immunoblots of VEcadherin or p120. e) HUVEC monolayers were pretreated with cycloheximide, or
cotreated with cycloheximide and bafilomycin A1, followed by addition of S1P. Cell surface
VE-cadherin was visualized by biotinylation. *P < 0.05 vs. DMSO control groups at the
same time course. Scale bar, 20 μm.
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Figure 6. Inhibition of recycling blocked sustained activity of S1P and recovery of cell surface
VE-cadherin. S1P-induced recycling of VE-cadherin was highlighted using Ca2+-switch protocol.
a) Endothelial electrical resistance was continuously recorded in HUVEC monolayers pretreated
with DMSO or bafilomycin A1, administered EGTA, and then post-treated with S1P+MCDB. b)
At completion of experiment (240 min), cells seeded directly on ECIS wells were visualized for
VE-cadherin by incubation with a rabbit anti-human VE-cadherin antibody. c) Representative
immunoblot of cell monolayers incubated with sulfo-NHS-SS-biotin to assess cell surface VEcadherin without or with bafilomycin A1. VE-cadherin in total cell lysate was used as loading
control. d) Quantification of four immunoblots in (c). Note that bafilomycin A1 decreased basal,
electrical resistance and blocked sustained increase in electrical resistance and also inhibited
increased recovery of cell surface VE-cadherin induced by S1P. *P < 0.05 vs. same treated
group in DMSO control. Scale bar, 5 μm.

To test whether or not the S1P-induced increase in cell surface VE-cadherin is
related to the bio-synthesis of VE-cadherin. HUVEC monolayers were pretreated for 2
h with 10 μg/ml of cycloheximide, an inhibitor of protein syntheses, or co-treated with
cycloheximide and bafilomycin A1 followed by administration of S1P for 1 h.
Cycloheximide interferes with the translocation step in protein synthesis thus blocking
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translational elongation. Cycloheximide alone failed to block the S1P-induced increase
in biotin-labeled, cell surface VE-cadherin (Fig. 5e). However, co-treatment with
cycloheximide and bafilomycin A1 blocked the effect of S1P. These data indicate that
the increase in cell surface of VE-cadherin by S1P is not due to an increase in
biosynthesis of VE-cadherin.

Further indication that S1P augmented the recycling of VE-cadherin was
demonstrated by incorporation of bafilomycin A1 with the Ca2+-switch protocol (Fig. 6).
Pretreatment with bafilomycin A1 decreased basal, endothelial electrical resistance,
suggesting that constitutive recycling of VE-cadherin contributes to the maintenance of
baseline barrier function (Fig. 6a). Following the precipitous drop in electrical resistance
with administration of EGTA, treatment with S1P+MCDB induced a rapid increase in
endothelial electrical that was sustained for the 3-h duration of the experiment.
Bafilomycin A1 blocked the sustained increase in endothelial electrical resistance (Fig.
6a).

These results indicate that basal resistance and the sustained increase in

endothelial electrical resistance induced by S1P were dependent on recycling.

At

completion of the electrical resistance experiment, cells seeded on the ECIS wells were
processed for the immunofluorescent staining of VE-cadherin. Junctional VE-cadherin
was present at 3h after treatment with S1P but was reduced in appearance in cell
monolayers pretreated with bafilomycin A1 (Fig. 6b). The biotinylation assay confirmed
these findings (Fig. 6, c and d). S1P increased the recovery of cell surface, biotinylated
VE-cadherin to a greater extent than MCDB (Fig. 6c, lane 4 vs. 3, and d) following the
initial reduction by EGTA. And pretreatment with bafilomycin A1 blocked the S1P- as
well as the MCDB-induced increase in biotinylated VE-cadherin at the cell surface (Fig.
6c, lanes 5 and 6 vs. lanes 3 and 4, and d).

S1P decreased EGTA-triggered endocytosis of VE-cadherin. Trafficking of VEcadherin is a dynamic process involving endocytosis and recycling, as well as
degradation. To determine if S1P directly affected the endocytosis of VE-cadherin,
recycling was inhibited with bafilomycin A1 and degradation was inhibited by
chloroquine which inhibits the lysosomal pathway of protein degradation.
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Before

labeling cell surface proteins with sulfo-NHS-SS-biotin, cell monolayers were pretreated for 1 h with bafilomycin A1 (1 μM) and the lysosomal inhibitor chloroquine (100
μM). Bafilomycin A1 caused an increase in biotinylated VE-cadherin in the cytoplasm
(Fig. 7a, lane 2), and S1P blocked this increase (lane 3), indicating that S1P decreased
the constitutive endocytosis of VE-cadherin. In the presence of bafilomycin A1 and
chloroquine, endocytosis of VE-cadherin was artificially triggered by EGTA following
pretreatment with Tris (as vehicle control) or S1P for 30 min. Pretreatment of S1P
decreased the EGTA-induced endocytosis of VE-cadherin (lane 5 vs. lane 4). The
decrease in endocytosis by S1P was also observed with immunofluorescence
microscopy (Fig. 7b). Within 2 min of EGTA administration, cells were separated and
strands extended between adjacent cells. In addition, internalized VE-cadherin localized
predominantly to the sub-plasma membrane. Administration of EGTA for 5 and 10 min
facilitated the endocytotic process, and internalized VE-cadherin was distributed
throughout the cytoplasm (Fig. 7b, top row). Pretreatment with S1P for 30 min reduced
the internalization of VE-cadherin by EGTA, and VE-cadherin was observed
predominantly at intercellular junctions throughout the 2-10 min-administration of EGTA
(Fig. 7b, bottom row).

Figure 7 also demonstrates that internalized VE-cadherin resided in early
endosomes identified with the early endosome antigen 1, EEA1. In the control setting,
VE-cadherin localized to intercellular junctions and EEA1 to cytoplasmic vesicles. Upon
administration of EGTA, VE-cadherin co-localized with EEA1 in cytoplasmic vesicles
when cells were pretreated with the Tris vehicle (Fig. 7c, column 2, merge row). In
contrast, pretreatment with S1P blocked this co-localization (column 3, merge row), and
VE-cadherin appeared prominently at intercellular junctions.
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Figure 7. S1P decreased
endocytosis of VE-cadherin
and blocked increase in colocalization of VE-cadherin
with EEA 1. The process of
endocytosis was separated
from
recycling
and
degradation
in
HUVEC
monolayers by using inhibitors
of the latter two (a) and by
pretreatment with S1P before
induction of endocytosis by
EGTA (a, b and c). a) Cells
were incubated with sulfoNIH-SS-biotin at 0°C for 1 h,
and pretreated for 1 h with
chloroquine
to
inhibit
degradation and bafilomycin
A1 to inhibit recycling. Cells
were pretreated with S1P to
determine its effects on
internalization of VE-cadherin
followed by addition of EGTA
for 10 min to induce
endocytosis. b and c) Cells
were pretreated for 30 min
with Tris or S1P followed by
administration of EGTA for 2,
5, and 10 min (b) and 10 min
only (c) to trigger endocytosis.
VE-cadherin was visualized
by incubation with a rabbit
anti-human
VE-cadherin
antibody and an Alexa
Fluor488-labeled secondary
antibody, and EEA1 by
incubation with a monoclonal
EEA 1 antibody and Alexa
Fluor594-labeled secondary
antibody. Scale bar (b and c),
10 μm.
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Microtubule inhibitors blocked S1P effects.

Microtubules provide the tracks for the

exocytosis of endocytic vesicles (16, 44). Thus, the involvement of microtubules was
tested by pretreatment for 1 h with either taxol to inhibit depolymerization (taxol binds to
β-subunit of tubulin on microtubules that locks the tubulin from disassembly) or
colchicine to inhibit polymerization of microtubules (colchicine binds to free tubulins that
results in blocking the nucleation of tubulins) followed by the Ca2+-switch protocol. Both
taxol and colchicine blocked the sustained increase in electrical resistance induced by
S1P in a dose-dependent manner (Fig. 8, a and b). As stated above, the sustained
endothelial electrical resistance induced by S1P was related to the restoration of
junctional VE-cadherin (Fig. 6b, 8c, DMSO control).

Immunofluorescent staining

showed that the recovery of junctional VE-cadherin by S1P+MCDB, following induced
endocytosis by EGTA, was attenuated by taxol and colchicine (Fig. 8c). These two
inhibitors of microtubules, however, did not prevent the EGTA-induced internalization of
VE-cadherin. These data demonstrate that the recycling of VE-cadherin induced by
S1P transported via microtubules.
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Figure 8. Microtubule inhibitors blocked effects of S1P. HUVEC monolayers were
subjected to the Ca2+-switch protocol and were either monitored continuously for
endothelial electrical resistance (a) or viewed for VE-cadherin by
immunofluorescence microscopy (b). Cells were pretreated for 1 h with DMSO
vehicle, or taxol or colchicine to inhibit microtubules. EGTA was added to induce
endocytosis of VE-cadherin followed by treatment with S1P+MCDB. a and b)
Endothelial electrical resistance was monitored continuously. c) VE-cadherin was
visualized by incubation with a rabbit anti-human antibody. Note that sustained
increase in electrical resistance and increased recovery of junctional VE-cadherin
induced by S1P were blocked by taxol and colchicines. Scale bar, 20 μm.
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DISCUSSION
The objective of this study was to demonstrate the cellular mechanism(s) for the
increase in junctional VE-cadherin induced by S1P within 10 min of treatment.

I

determined using immunofluorescence microscopy and a quantitative biotinylation
assay that S1P decreased the endocytosis and increased the recovery of cell surface
VE-cadherin induced by EGTA and VEGF.

Furthermore, S1P increased the co-

localization of internalized VE-cadherin with Rab11 and blocked and reversed the
VEGF-induced interaction of VE-cadherin with β-arrestin2.

Finally, inhibitors of the

recycling process or microtubules blocked the S1P-induced increase in junctional
appearance of VE-cadherin.

I conclude that S1P rapidly increases junctional VE-

cadherin by decreasing the endocytosis and increasing the recycling of VE-cadherin.
Synthesis and degradation and in the case of a membrane protein such as VEcadherin movement in and out of the cell can determine the amount and cellular
localization of a protein. The increase in junctional VE-cadherin induced by S1P does
not appear to involve synthesis because it can occur within 10 min of treatment. Further,
inhibition of protein synthesis with cycloheximide had no effect. Therefore, I focused on
membrane trafficking of VE-cadherin involving the endocytosis of the protein from the
cell surface to intracellular endosomes and recycling back to the cell surface through
recycling endosomes. Herein, I demonstrated that S1P opposed the effects of VEGF as
well as EGTA on decreasing endothelial electrical resistance, reducing VE-cadherin at
intercellular junctions, increasing the endocytosis of VE-cadherin, and increasing the
interaction of β-arrestin2 with VE-cadherin. Previous studies have demonstrated that
VE-cadherin constitutively internalizes via a clathrin-dependent pathway (42).
Trafficking of E-cadherin has been extensively studied by Stow et al. (4). Using the
biotinylation assay, these investigators found that 13% of cell surface E-cadherin is
constitutively internalized and recycled back to the cell surface (20), and that this
process is mediated by protein kinase C and Rac1 (1, 19).

Trafficking of E-cadherin

appears to regulate cell-cell adhesion, morphogenesis and signaling downstream of the
active fibroblast growth factor receptor 1 (1, 4, 5).
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VE-cadherin also appears to

constitutively undergo endocytosis and recycling (43), and trafficking of VE-cadherin
has been postulated to be involved in angiogenesis and regulation of endothelial barrier
function (42, 43). Endocytosis induced by VEGF has been hypothesized as the cellular
mechanism for the permeability-increasing activity of VEGF (15). The binding of VEGF
to its VEGF2 receptor initiates the activation of Src leading to a sequence of events
including activation of Vav2 (a guanosine exchange factor for the Rho family of
GTPases), Rac1, and p21-activated kinase (PAK).

Active PAK induces the

phosphorylation of Ser665 on VE-cadherin providing a signaling site for the interaction
with

beta-arrestin2

(endocytic

adaptor

protein)

and

allowing

for

subsequent

internalization of VE-cadherin via a clathrin-dependent pathway (15, 42). Interestingly,
S1P like VEGF activates Rac1 and PAK (14), and inhibition of Rac1 diminishes the
immunofluorescent staining of VE-cadherin at intercellular junctions (28).
Stow et al. (4, 20) showed that most of the endocytic vesicles containing Ecadherin were recycled back to the cell membrane and were not targeted for
degradation, and that recycling of E-cadherin to the cell surface predominated over
degradation, promoting stabilization of the barrier. This was evident when cells were
treated with bafilomycin A1, an inhibitor of recycling endosomes.

Furthermore, E-

cadherin present in endocytic vesicles co-stained with rab5, a marker of early
endosomes, but did not co-localize with the late endosomal marker rab7 (20). Rab11
locates at recycling endosomes and acts as an intermediate compartment for the postGolgi trafficking of E-cadherin (23). In the present study, S1P increased the recycling of
internalized VE-cadherin back to the cell surface, as assessed by immunofluorescence
microscopy and the biotinylation assay.

The recycling inhibitor, bafilomycin A1,

prevented the S1P-induced increase in junctional VE-cadherin under normal conditions
and during the Ca2+-switch protocol.
Endocytosed vesicles first sort into early-endosomes, and then either go through
late endosomes, lysosomes to be degraded, or transport back to cell membrane via
recycling endosomes. Early, recycling, and late endosomes are populated by specific
Rab GTPases that cluster in these distinct domains with their effectors (37).
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Rab

proteins, in their active form, assemble with their effectors in responsible for vesicle
budding, cytoskeletal transport, and target membrane fusion (38).

Internalized VE-

cadherin and E-cadherin co-localize with Rab5 found in early endosomes and EEA1, an
effector of Rab5 (15, 20). But, internalized E-cadherin induced by increasing
temperature did not localize with Rab7, a marker of late endosomes (20). In the present
study, VE-cadherin containing vesicles were initially localized to the subplasma
membrane after 2 min of EGTA administration. With longer administration of EGTA (510 min), these vesicles distributed throughout the cells coinciding with EEA1. S1P
blocked the co-localization of internalized VE-cadherin and EEA1.
Rab4 and Rab11 cluster in recycling endosomes and comprise the machinery
that recycles proteins to the cell surface (33, 38).

Expression of a Rab11 mutant

deficient in GTP binding significantly slowed transferrin-receptor recycling back to the
cell membrane (30).

For β2-adrenergic receptors, Rab11 regulates recycling and

targeting to lysosomes. Further, Rab11 acts as an intermediate compartment to
regulate the post-Golgi trafficking and exocytosis of E-cadherin (23). Recycling
endosomes distribute throughout the cell but also localize prominently in a cluster called
the perinuclear recycling endosome.

Following treatment with EGTA for 10 min,

internalized VE-cadherin was distributed throughout the cell in coincidence with
expressed EGFP-Rab11 but was prominently clustered with EGFP-Rab11 in
perinuclear recycling endosomes. Within 5-min of treatment with S1P, co-localization
was apparent at the subplasma membrane. After 10-min of treatment, VE-cadherin
appeared to a lesser degree in the perinuclear recycling endosome, still resided with
Rab11 at the subplasma membrane, and reappeared at the cell periphery. In contrast,
internalized VE-cadherin co-localized with Rab11 only in the perinuclear recycling
endosomes in MCDB-treated group.

These data suggest that S1P enhanced the

recycling of VE-cadherin via the Rab11 GTPase.
It was reported that S1P triggered exocytosis in bovine chromaffin cells (32),
increased glutamate secretion in neurons (18), and also facilitated the endothelial
exocytosis of Weibel-Palade bodies in part by activating of phospholipase C (PLC)-γ
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pathways (25). Transportation of intracellular vesicles to cell membrane is a kind of
exocytosis that involves the recycling process, and elevated intracellular Ca2+ level
plays a role in exocytosis. Interestingly, S1P rapidly increases the intracellular level of
Ca2+ in many cell types (32, 35, 46).
Endocytosis, recycling, and degradation are dynamic processes making it difficult
to separate the effects of S1P on these three processes.

The bafilomycin A1

experiments clearly implicate recycling in the increased junctional localization of VEcadherin induced by S1P. In the attempt to separate the effects of S1P on endocytosis,
recycling and degradation were inhibited, respectively, by bafilomycin A1 and
chloroquine. Also, S1P was pretreated for 30 min before administration of EGTA for 2,
5, and 10 min. Immunofluorescence microscopy and the quantitative biotinylation assay
demonstrated that S1P decreased the endocytosis of VE-cadherin. I conclude that S1P
can regulate both endocytosis and the recycling processes of VE-cadherin that result in
the increased presence of junctional VE-cadherin and stabilization of the endothelial
barrier.
S1P was reported to increase microtubule polymerization (31). Microtubule
cytoskeletons, together with the microtubule-based motor proteins, kinesin and dynein,
have been shown to play important roles in membrane trafficking events involved in
endocytosis and transcytosis (6, 22, 44). The cadherin-catenin complex and N-cadherin
were shown to transport to the intercellular junctions along microtubule cytoskeletons
and driven by kinesin (24, 31). To further prove that the S1P-enhanced junctional VEcadherin is through regulation of vesicle trafficking via microtubules, cells were treated
with microtubules inhibitors, taxol and colchicine. Taxol and colchicine stabilize
microtubules by inhibiting depolymerization or polymerization, respectively. Sokolova et
al. (36) reported that depolymerization of microtubules has no effects on EGF
internalization, and I also found that both taxol and colchicines have no influence on the
EGTA-induced endocytosis of VE-cadherin. However, taxol and colchicine blocked the
restoration of immunofluorescent localization of VE-cadherin at cell junctions and
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prevented the S1P-induced maintenance of electrical resistance which is associated
with junctional VE-cadherin, as originally demonstrated in our previous study (45).
With respect to endocytosis and recovery of cell surface VE-cadherin, S1P and
VEGF induced opposite responses. Interestingly, when VEGF and S1P were co-treated
or when VEGF was pretreated for 30 min followed by post-treatment for 30 min with
S1P, the end results favored the effects of S1P. This complementary response would
implicate a transactivation event involving a receptor tyrosine kinase and a G-proteincoupled receptor (GPCR). S1P triggers intracellular signaling via binding to G-proteincoupled receptors, i.e. Edg receptors. Likewise, VEGF up-regulates the expression of
S1P1 receptors in bovine aortic endothelial cells, which was associated with enhanced
intracellular signaling responses to S1P and the potentiation of S1P-mediated
vasorelaxation (17). Tanimoto et al. (39) reported that S1P activates not only S1P
receptors but also activates the VEGF receptor Flk-1/KDR faster than VEGF
stimulation. Endo et al. (12) proved that S1P induces membrane ruffling of human
umbilical vein endothelial cells (HUVECs) via the vascular endothelial growth factor
receptor (VEGFR), Src family tyrosine kinase(s), and the CrkII adaptor protein. Similarly
epithelial growth factor (EGF) receptor, platelet derived growth factor (PDGF) receptor
and insulin-like growth factor in response to activation of G-protein-coupled receptor
(GPCR) has been reported (10, 11). VEGF binds to VEGF R2 that results in increases
in permeability and endocytosis of VE-cadherin (15). In this paper, VEGF decreased the
endothelial electrical resistance and increased the endocytosis of VE-cadherin, and S1P
induced the opposite effects. In view of that, S1P protects endothelial barrier from the
effects of VEGF via regulating VE-cadherin trafficking, and possibly involving the
crosstalk between receptors of S1P and VEGF.
Going over the main points in this paper, I demonstrated that S1P enhances the
endothelial barrier by regulating VE-cadherin trafficking via decreases in endocytosis
and increases in recycling of VE-cadherin. The recycling of VE-cadherin transports
along microtubules.
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Study 3

p120 is potentially involved in the regulated VE-cadherin
trafficking by S1P

Keywords: kinesin, microtubule, Rab11, recycling endosome, human
umbilical vein endothelial cell.
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ABSTRACT
My previous studies demonstrated that S1P regulates VE-cadherin trafficking by
decreasing endocytosis and increasing recycling of VE-cadherin. However, what
mechanisms contribute to these regulatory effects of S1P are still unclear. In this study,
I found that under normal conditions (without EGTA), S1P increased the interaction of
VE-cadherin with p120 and augmented the co-localization of VE-cadherin with p120 at
cell-cell junctions; furthermore, S1P enhanced the association of p120 with biotinylated,
cell surface VE-cadherin. After administration of EGTA to induce endocytosis of VEcadherin, association of p120 with VE-cadherin was increased by S1P as compared to
the control treatment (MCDB) in HUVECs. S1P enhanced the co-localization of p120
with Rab11, a marker of recycling endosomes, and the interaction of p120 with kinesin,
a motor protein moving along microtubules. In contrast, VEGF, previously demonstrated
to induce endocytosis of VE-cadherin via increased interaction of VE-cadherin with βarrestin2 (12), decreased the interaction of VE-cadherin with p120 in BPAEC
monolayers. In addition, co-treatment of S1P with VEGF or post-treatment with S1P
following pretreatment with VEGF blocked or reversed, respectively, the VEGF-induced
effects. I conclude that the regulatory effects of S1P on VE-cadherin trafficking
potentially occur through the increased interaction of VE-cadherin with p120, and the
interaction of p120 with kinesin.
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INTRODUCTION
In my previous studies, I demonstrated that sphingosine 1-phosphate (S1P)
enhances the endothelial barrier through regulation of VE-cadherin trafficking, i. e.
decreasing endocytosis and increasing recycling of VE-cadherin. What cellular
mechanisms contribute to this regulatory effects of S1P, however, are unclear. VEcadherin, a main protein of adherens junctions, stabilizes the endothelial barrier through
homophilic binding of its extracellular region (5, 15). The cytoplasmic tail of VE-cadherin
interacts with β-catenin and plakoglobin (γ-catenin) which bind to α-catenin. α-Catenin in
turn directly interacts with actin filaments. This sequential linkage, however, is
controversial as one study has reported that α-catenin does not bind simultaneously to
actin and β-catenin (37). p120 catenin (p120) is the fourth catenin at the adherens
junction. p120 binds to the cytoplasmic tail of VE-cadherin at the juxtamembrane
domain and plays a crucial role to stabilize VE-cadherin. p120 also regulates adherens
junctions indirectly through its functional connections with Rho GTPases (2, 3, 14, 28).
p120, a member of the armadillo family of proteins, consists of an NH2-terminal
head domain, an ARM domain with 10 ARM repeats which is involved in the interaction
of p120 with cadherin, and a short COOH-terminal domain (4, 30). p120 was first
described as a substrate of Src and other tyrosine kinases, but p120 is constantly found
having multiple roles in cellular activities, well known as a stabilizer of cadherin (4, 10,
16). Interaction of p120 with VE-cadherin regulates the expression of VE-cadherin
which influences the regulation of the endothelial barrier. Gene silencing of p120 or
mutation of the juxtamembrane domain on p120 binding site of VE-cadherin decreased
the level of VE-cadherin, which was accompanied with internalization and degradation
of VE-cadherin (17, 34, 35). Whereas increasing or overexpression of p120 enhanced
the level of VE-caderin. Decreases in the p120 level caused a loss of barrier function,
however, overexpression of p120 also disrupted endothelial barrier (17). Hence, p120
plays an important role in regulating endothelial barrier function. p120 regulates not only
VE-cadherin but also other cadherins. Gene silencing of p120 in cells expressing
epithelial (E-), placental (P-) and neuronal (N-) cadherin induced rapid degradation of

79

each cadherin, as well as α- and β-catenin, that resulted in the loss of adherens
junctions (10).
In addition to interacting with cadherins, p120 associates with cortactin via the
cortactin N-terminal region to regulate lamellipodial dynamics and cell adhesion (6).
Interestingly, Anastasiadis et al. (38) reported that p120 can traffic along microtubules
via the direct interaction of its N-terminal region with the kinesin heavy chain. Kinesin is
a motor protein and transports vesicles from minus end to plus end (cell membrane)
along microtubules (21, 24, 25). p120 recruits and interacts with kinesin, this interaction
regulates not only localization and function of p120, but also facilitates the transport of
cadherin-catenin complexes to intercellular junctions (8, 38).
In my second study, I demonstrated that S1P-induced recycling of VE-cadherin
traffics along microtubules. Mary et al. (26) reported that microtubules and kinesin are
crucial for the transport of N-cadherin to intercellular junctions. Furthermore, Paik et al.
(29)

showed

that

S1P

induced

microtubule

polymerization,

regulated

the

phosphorylation of N-cadherin and p120, and mediated trafficking of N-cadherin to the
polarized plasma membrane. Here, I provide evidence that p120 potentially is involved
in the effects of S1P on the regulation of VE-cadherin trafficking. Enhanced interaction
of p120 with VE-cadherin by S1P in normal or Ca2+-switch experiments was
investigated by using co-immunoprecipitation and biotinylation methods and visualized
by confocal immunofluorescence microscopy. EGFP-tagged Rab11, a marker of the
recycling endosome, was transfected into HUVECs to investigate the co-localization of
p120 with recycling endosomes. The increased interaction of p120 with kinesin by S1P
was investigated by co-immunoprecipitation.
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MATERIALS AND METHODS

Materials.

S1P was purchased from Avanti Polar Lipids (Alabaster, AL).

Bovine

pulmonary artery endothelial cells were purchased from Vec Technologies, Inc.
(Rensselaer, NY). Gentamicin sulfate was from ICN Biomedicals, Inc. (Aurora, OH).
Newborn calf serum and bovine brain extract were from Cambrex Corporation (East
Rutherford, NJ). Sulfosuccinimidyl 2-(biotinamido) ethyl-dithioproprionate (sulfo-NHSSS-biotin) was purchased from Pierce (Rockford, IL). Recombinant human VEGF 165
was purchased from R&D systems, Inc. (Minneapolis, MN). Prolong Gold anti-fade
reagent and Alexa Fluor-labeled secondary antibodies were from Invitrogen Molecular
Probes (Eugene, OR). VE-cadherin antibodies were purchased from Axxora (San
Diego, CA) and Beckman Coulter Company (Marseille Cedex, France). Beta-catenin
antibody was from BD Bioscience (San Jose, CA). p120-catenin antibody and protein
A/G beads were from Santa Cruz Biotechnology (San Diego, CA).

Horseradish

peroxidase conjugated secondary antibodies and mouse anti-kinesin heavy chain
antibody (clone 2) were purchased from Chemicon International (Temecula, CA).
Nitrocellulose membranes and ECL (enhanced chemiluminescence) Western blotting
detection reagents were purchased from Amersham Biosciences (Buckinghamshire,
England). EGFP-tagged Rab11 was a gift from Dr. Karen Martin. All other chemicals
were from Sigma-Aldrich (St. Louis, MO).
Cell culture. Human umbilical vein endothelial cells (HUVEC) were isolated from fresh
human placentas by 1 mg/ml of type I collagenase and grown in MCDB-131 (MCDB)
culture medium containing 5% (v/v) human serum, 20% (v/v) newborn calf serum, 7.5
μg/ml of endothelial cell growth supplement, 4.5 μg/ml of bovine brain extract, 25 μg/ml
of porcine intestinal heparin, and 50 μg/ml of gentamicin sulfate at 37°C in 5% CO2.
HUVECs were used between passages 2 and 8.
monolayers were serum-starved for 2 h.

Before treatments, HUVEC

Bovine pulmonary artery endothelial cells

(BPAEC, passages 3-18) were cultured in MCDB medium containing 10% fetal bovine
serum and 50 μg/ml of gentamicin sulfate. BPAEC monolayers were serum-starved for
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4 h before treatments. HUVECs were used for all experiments except for experiments
with VEGF.
Ca2+-switch protocol. Cell monolayers were treated with 2 mM EGTA (ethylene glycolbis(2-amino-ethylether)-N,N,N’,N’-tetra-acetic acid) for 10 min to chelate extracellular
Ca2+, followed by (1) adding nothing, (2) adding fresh MCDB containing 1.6 mM Ca2+ to
restore extracellular Ca2+, or (3) adding 1 μM S1P and fresh MCDB.

Immunofluorescence microscopy.

After treatments, cell monolayers were rinsed

quickly with phosphate-buffered saline containing Ca2+ and Mg2+ (PBS+/+). Cells were
fixed, permeabilized, and incubated with 5% BSA.

Cells were then incubated with

primary antibodies, followed by Alexa Fluor-labeled secondary antibodies, and rinsed
several times with PBS+/+. Cells were mounted with Prolong Gold anti-fade reagent.
Images were generated by confocal laser scanning with a Zeiss LSM 510 confocal
microscope. For the same group of images, the fluorescent signals were measured at
emission wavelengths of 488 and 594 nm with the same pinhole (less than 1 μm), the
same detector gain, and the same amplifier offset.
Transfection. Enhanced GFP (EGFP)-tagged Rab11 was transfected into HUVECs by
electroporation with the Nucleofector I device (Amaxa Biosystems, Berlin, Germany).
Briefly, 90% confluent HUVEC monolayers were trypsinized and counted.

After

centrifugation, 1.0x106 cells were resuspended in 100 μl of Nucleofector solution (7.25
mM ATP, 12 mM MgCl2 ⋅ 6H2O, 88 mM KH2PO4, 14 mM NaHCO3, and 2 mM glucose at
pH 7.4) with EGFP-tagged Rab11 and transferred immediately to a cuvette and
electroporated in the Nucleofector apparatus, using program U-001. Transfected cells
were recovered with fresh medium at 37°C for 5 min and seeded on gelatin-coated
glass cover-slips. Cells were placed in a humidified environment and maintained at
37°C and 5% CO2 for 2 d until used for experimentation.
Immunoblotting. Cells were washed 2x in ice-cold PBS, lysed in RIPA buffer (15 mM
NaCl, 50 mM Tris, 1% NP-40, 0.5% sodium deoxycholate) containing 2 mM EGTA, 1
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mM sodium vanadate, 1 mM phenylmethanesulfonyl fluoride (PMSF), 5 μg/ml of
aprotinin, and 2 μg/ml of leupeptin. Samples were clarified by centrifugation at 14,000
rpm for 10 min at 4°C.

Proteins were resolved by sodium dodecyl sulfate-

polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to Nitrocellulose
membrane using a mini-Protean electrophoresis system. Protein blots were probed
with indicated primary antibodies, followed by the appropriate horseradish peroxidaseconjugated secondary antibody, and developed by enhanced chemiluminescence.

Biotinylation assay for assessment of cell surface VE-cadherin.

Cell surface VE-

cadherin and membrane protein-bound p120 were quantified by using a biotinylation
assay (7, 22).

Cell surface proteins were covalently labeled with 1.0 mg/ml of

sulfosuccinimidyl 2-(biotinamido) ethyl-dithioproprionate (sulfo-NHS-SS-biotin), a biotinlabeled cell impermeable reagent. Briefly, after indicated treatments, cells were
incubated at 0°C with the sulfo-NHS-SS-biotin for 1h, followed by washing with blocking
buffer to quench free biotin. Cells were lysed in RIPA buffer with protease inhibitors.
Equal amounts of proteins were incubated with streptavidin beads and resolved by
SDS-PAGE. Biotinylated, cell surface VE-cadherin was identified with an anti-VEcadherin antibody to the extracellular domain. p120 immunoprecipitated in biotin was
identified with a rabbit anti-p120 antibody.

Co-immunoprecipitation.

Cells were lysed in RIPA buffer with phosphatase and

protease inhibitors, and lysates were centrifuged at 14,000 rpm for 10 min at 4°C to
clear debris.

About 2 mg of protein was incubated with a rabbit anti-human VE-

cadherin antibody or mouse anti-bovine kinesin heavy chain antibody for 2 h at 4°C
after preclearing with 50 μl of protein A/G beads for 1 h. Protein A/G beads were added
and incubated for additional hour to pull down antibody-bound proteins. Beads were
washed with RIPA buffer several times and boiled in 3x sample buffer. Proteins were
resolved and analyzed by Western blotting.
Statistics. All values are means ± SE and were obtained in at least four separate
experiments.
83

RESULTS
S1P increased interaction of VE-cadherin with p120. Within 10 min of treatment,

Figure 1. S1P increased interaction of VE-cadherin with p120. HUVEC monolayers were
treated with 1 μM S1P, and co-localization and interaction of VE-cadherin with p120 were
determined by immunofluorescence microscopy (a), immunoprecipitation (b) and cell
surface biotinylation (c). (a) Cells were treated with S1P for 10 mim, then stained by
mouse anti-human VE-cadherin and rabbit anti-mouse p120 antibodies. (b) Cell lysates
were immunoprecipitated with a rabbit anti-human VE-cadherin antibody against N-terminal
domain to pull down VE-cadherin-bound proteins and resolved on SDS-PAGE. p120,
kinesin and VE-cadherin were identified by p120, VE-cadherin or mouse anti-bovine kinesin
heavy chain antibodies. (c) Cell surface proteins were incubated with sulfo-NHS-SS-biotin
at 0°C after S1P treatments, and equal amount of protein was incubated with streptavidin
beads to complex biotin-labeled proteins. VE-cadherin and p120 were identified by the
antibodies used in (b). Blot is representative of 3 separate experiments. Scale bar, 10 μm.

1 μM S1P increased the co-localization of immunofluorescent staining of VE-cadherin
and p120 at intercellular junctions (Fig. 1a). This increased association of VE-cadherin
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with p120 was also demonstrated by co-immunoprecipitation and biotinylation (Fig. 1b,
c). S1P enhanced the interaction of VE-cadherin with p120 at 5 min (Fig. 1b, top
bands). Interestingly, the interaction of VE-cadherin with kinesin did not increase until
30 min (Fig. 1b bottom bands). S1P increased biotinylated, cell surface VE-cadherin at

Figure 2. S1P enhanced the interaction of p120 with recycled, cell surface VE-cadherin.
Interaction of p120 with recycled VE-cadherin was performed by pretreatment with 2 mM
EGTA to reduce cell surface VE-cadherin and post-treatment with or without S1P. (a) Cell
surface VE-cadherin and p120 were assessed by the biotinylation method. (b)
Quantification of four immunoblots shown as a ratio of individual band to control band.

10 and 60 min (also demontrated in study 2) (Fig. 1c, top bands), and also biotinylated,
cell surface protein-bound p120 (Fig. 2c, bottom bands).
S1P enhanced the interaction of p120 with recycled VE-cadherin. Quantitative
measurement of the interaction of cell surface protein-bound p120 with cell surface VEcadherin was highlighted by using the Ca2+-switch protocol. Administration of 2 mM
EGTA decreased most of biotinylated, cell surface VE-cadherin (Fig. 2a, top
band/second lane), but just partially decreased the level of p120 (Fig. 2a, bottom
band/second lane). Subsequently, HUVEC monolayers were post-treated with MCDB to
restore extracellular Ca2+ with or without S1P. Post-treatment with S1P plus MCDB
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recovered cell surface VE-cadherin to a greater extent than those post-treatments

Figure 3. S1P increased the co-localization of p120 with recycled VE-cadherin. HUVEC
monolayers were pretreated with 2 mM EGTA to reduce cell surface and increase
internalized VE-cadherin followed by post-treated with or without S1P. VE-cadherin was
visualized by incubation with a mouse anti-human VE-cadherin primary antibody (Cad 5)
and an Alexa Fluor 594-labeled goat anti-mouse secondary antibody. p120 was visualized
by incubation with a rabbit anti-mouse p120 antibody and an Alexa Fluor488-labeled goat
anti-rabbit secondary antibody. Note that p120 co-localized with VE-cadherin at the
peripheral region in the groups treated with S1P for 5 min, and co-localized with VEcadherin at both peripheral and junctional area in the groups treated with S1P for 10 min.
Scale bar, 10 μm.

without S1P (Fig. 2a, b, top bands/bar, 4th, 6th and 8th lane/bar vs. 3rd, 5th and 7th
lane/bar). Accompanied increase of p120 with increased recycled, cell surface VEcadherin was observed (Fig. 2a, b, bottom bands/bar). In addition, the interaction of
p120 with VE-cadherin was higher in the S1P-treated groups compared with the MCDB
groups (Fig. 2a, b, bottom bands/bars, 4th, 6th and 8th lane/bar vs. 3rd, 5th and 7th
lane/bar).
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The increased interaction of p120 with recycled VE-cadherin by S1P was
confirmed by immunofluorescent staining (Fig. 3). VE-cadherin co-localized with p120 at
the intercellular junctions observed in the control setting (Fig. 3, control column).
Administration of EGTA caused decreases in junctional VE-cadherin and p120, a
reduction of the co-localization of VE-cadherin with p120, and induced internalization of
VE-cadherin and p120 from the junction to cytoplasm (Fig. 3, 2nd column). p120
disassociated from internalized VE-cadherin and did not co-localize with it (Fig. 3,
merge row, 2nd column). However, post-treatment with S1P for 5 min facilitated the
transport of internalized VE-cadherin and p120 to the cell peripheral area (Fig. 3, top
and middle row, 3rd column) and increased the co-localization of p120 with VE-cadherin
at these regions (Fig. 3, merge row, 3rd column). At 10 min, there was an obvious codistribution of junctional VE-cadherin and p120 (Fig. 3, 4th column). There was no colocalization of p120 with VE-cadherin after post-treatment with MCDB for 5 min and
limited co-localization was observed at 10 min (Fig. 3, merge row, 5th column). These
data suggest that S1P increases the transport of VE-cadherin and p120 to adherens
junctions.
S1P increased co-localization of p120 with Rab11. To test if p120 plays a role
during the S1P-facilitated recycling process, enhanced GFP-tagged Rab11 was
transiently electroporated into HUVECs, and cells were visualized by confocal
microscopy. p120 was reduced at cell junctions by administration of EGTA (Fig. 3 and
4). Post-treatment of S1P for 5 min induced co-localization of p120 with Rab11 at the
subplasma membrane and at the intercellular junction (Fig. 4, 3rd column). No
interaction of p120 with Rab11 was observed in the MCDB-treated group (Fig. 4, 4th
column).
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Figure 4. S1P increased co-localization of p120 with Rab11. EGFP-tagged Rab11 was
transiently transfected into HUVECs by electroporation. After 48 h, cell monolayers were
treated with or without S1P following pretreatment with EGTA. p120 was visualized by
incubation with a rabbit anti-mouse p120 antibody and an Alexa Fluor 594-labeled goat antirabbit secondary antibody. Note that p120 co-localized with Rab11 at the peripheral area
within 5 min in S1P treated group. Scale bar, 5 μm.

S1P increased interaction of p120 with kinesin. Data in study 2 demonstrated
that S1P facilitated recycling of VE-cadherin through microtubules (study 2, Fig. 9).
Kinesin, a plus-end directed motor protein, facilitates transport of vesicles along
microtubules (24, 25). Interestingly, p120 was reported to associate with kinesin and
facilitate transport of cadherin-catenin complexes to intercellular junctions (8). Herein, I
tested how p120 is involved in the effects of S1P to facilitate the transport of VEcadherin. The Ca2+-switch protocol was applied to induce endocytosis of VE-cadherin
followed by post-treatment with or without S1P to restore cell surface VE-cadherin. The
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interaction of p120 with kinesin was assessed by co-immunoprecipitation. Posttreatment with S1P dramatically enhanced the interaction of p120 with kinesin within 5
and 10 min of treatment compared to post-treatment with MCDB alone (Fig. 5).
Together the data in Figures 2 and 3 suggest that S1P increases recycling of VEcadherin back to cell surface by increasing the interaction of recycling VE-cadherin with
p120 and recruiting kinesin to the complex and facilitating recycling of VE-cadherin.

Figure 5. S1P increased interaction of p120 with kinesin. HUVEC monolayers were posttreated with or without S1P for 5, 10 and 30 min following pretreatment with EGTA. Cell
lysates were incubated with a mouse anti-bovine kinesin heavy chain antibody (clone 2) to
complex kinesin-bound proteins and immunoblotted for p120 and kinesin. Blot is
representative of 4 separate experiments. Note that S1P increased interaction of p120 with
kinesin compared to MCDB group.

S1P inhibited and reversed decreased interaction of VE-cadherin with p120 by
VEGF. Since EGTA, used to induce endocytosis of VE-cadherin, is not a physiological
reagent, I next studied the effects of S1P on the interaction of VE-cadherin with p120 in
BPAEC monolayers using the physiological mediator VEGF.

VEGF decreased the

interaction of VE-cadherin with p120 in a time-dependent manner (Fig. 6, lane 2 and 3),
but S1P increased this interaction in the same temperal manner (Fig. 6, lane 4 and 5).
Furthermore, co-treatment of S1P with VEGF and post-treatment with S1P after pretreatment with VEGF for 30 min blocked and reversed, respectively, the VEGF-induced
decrease in interaction of VE-cadherin with p120 (lane 6 and 7). These data suggest
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that the cellular mechanism of S1P protection from the vascular barrier effects of VEGF
may occur through regulation of the interaction of p120 with VE-cadherin.

Figure 6. S1P inhibited and reversed decreased interaction of VE-cadherin with p120
by VEGF. Endothelial cell monolayers derived from bovine pulmonary arteries
(BPAEC) were treated individually with S1P or VEGF or in combination or pretreated
for 30 min with VEGF then post-treated for 30 min with S1P. Cell lysates were
immunoprecipitated with a rabbit anti-human VE-cadherin antibody and
immunoblotted for p120 and VE-cadherin. Note that VEGF decreased the interaction
of VE-cadherin with p120, S1P increased it and co-treatment or post-treatment with
S1P blocked and reversed VEGF effects. Blot is representative of 3 separate
experiments.
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DISCUSSION
In this study, the role of p120 in the S1P effects on regulation of VE-cadherin
trafficking were investigated. Xiao et al. (10, 34-36) reported that p120 is crucial for
regulating expression and trafficking of VE-cadherin. Paik et al. (29) showed that p120
was involved in N-cadherin trafficking mediated by S1P. Here, I demonstrated that S1P
increased co-localization and interaction of p120 with VE-cadherin in whole cell lysate
and at the cell surface. EGTA or VEGF were applied to highlight the study of S1P
effects on the trafficking of VE-cadherin. S1P increased recycling of VE-cadherin to a
greater extent and faster than MCDB (also demonstrated in study 2), and this increase
was accompanied with an increased interaction and co-localization of p120 with
recycled, cell surface VE-cadherin, as well as with Rab11. Interestingly, S1P also
enhanced the interaction of p120 with kinesin. Furthermore, S1P blocked and reversed
the VEGF-induced decrease in interaction of VE-cadherin with p120. I conclude that
S1P increases VE-cadherin trafficking through enhanced interaction of p120 with VEcadherin and with kinesin to facilitate this transport.
Interaction of p120 with VE-cadherin is important for maintenance of endothelial
barrier function (17), and this is a dual interactions: one, p120 interacts with cell surface
VE-cadherin to stabilize junctional VE-cadherin; two, p120 interacts with recycled VEcadherin in the cytoplasm. In the first case, Xiao et al. (35, 36) reported that p120 works
as a cap to interact with the cytoplasmic tail of VE-cadherin and inhibits the endocytosis
of VE-cadherin. I found that S1P increased the association of p120 with cell surface VEcadherin and inhibited the dynamic endocytosis of VE-cadherin (demonstrated in study
2). Hence, during the normal situation, S1P enhances junctional VE-cadherin via an
increase in the interaction of p120 with cell surface VE-cadherin. However, it is unclear
if p120 also interacts with internalized VE-cadherin, I did not see any co-localization of
p120 with cytoplasmic VE-cadherin in the control group (Fig. 1a), but this may be due to
the small amount of VE-cadherin that dynamically internalizes. Interestingly, p120 was
reported to facilitate transport of itself and cadherin-catenin complex to cell-cell
junctions (8, 38), so the interaction of cytosolic p120 with recycling cadherin may
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influence the recycling process. EGTA or VEGF was added to augment the
internalization

of

VE-cadherin.

During

the

initial

endocytosis

process,

p120

disassociated from internalized VE-cadherin and no-co-localization was observed as
previously reported by Xiao et al. (35). When S1P was added to launch the recycling
process of VE-cadherin (demonstrated in study 2), p120 interacted primarily with
recycled VE-cadherin and coincidently with Rab11, a marker and pivotal protein of
recycling endosomes. p120 also interacted with cell surface VE-cadherin following the
recovery process. So far, the role of the small GTPase, Rab11, in the transport of VEcadherin facilitated by p120 is not characterized.

In summary, S1P facilitated the

recycling of VE-cadherin possibly through an enhanced interaction of p120 with
recycled cell surface VE-cadherin.
The role of p120 in S1P effects may also involve the Rho family of GTPases.
Rho family GTPases, such as Rac1, RhoA and Cdc42 are important for regulation of
the endothelial barrier, actin cytoskeleton, cell spreading and migration, as well as
cadherin trafficking (1, 18-20, 31-33). S1P activates Rac1, Cdc42, as well as RhoA and
remodels the actin cytoskeleton (9, 13, 23, 27). p120 was reported to bind to the Rho
family exchange factor Vav2 to activate Rac and Cdc42 (28) and even directly to Rho A
through its Arm domain (11). Therefore, the sequence and linkage among S1P, Rho
family GTPases and p120 with regard to VE-cadherin trafficking need further
investigation.
Interaction of β-arrestin2 with VE-cadherin triggers internalization of VE-cadherin.
VEGF was reported to induce endocytosis of VE-cadherin through a β-arrestin2dependent pathway (12). In study 2, I found that S1P had the opposite effect. S1P
suppressed and reversed the VEGF-induced interaction of VE-cadherin with β-arrestin2.
Moreover, the present study identified that VEGF decreased the interaction of p120 with
VE-cadherin. In contrast, S1P increased this interaction and co-treatment or posttreatment with S1P suppressed or reversed the VEGF effects. β-arrestin2 binds to a
conserved, phosphorylated Ser-Val-Arg (SVR) motif on the intracellular domain of VEcadherin where the SVR motif is just adjacent to the p120 binding region (12). The
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increased interaction of p120 with VE-cadherin by S1P may cap the intracellular domain
of VE-cadherin and inhibit the binding of β-arrestin2 to VE-cadherin. S1P may also
regulate the phosphorylation level of the SVR motif, which in turn blocks VE-cadherin
endocytosis. All of these hypotheses need to be studied in the future.
Microtubules together with kinesin play a crucial role in the transport of Ncadherin to cell-cell junctions (26, 29). p120 can directly associate with kinesin and
microtubules (11). The interaction of p120 with kinesin facilitates the transport of p120
and the cadherin-catenin complex (8, 38). In study 2, I demonstrated that S1P regulated
VE-cadherin trafficking via microtubules (study 2, Fig. 8). The present study revealed
that S1P increased the interaction of p120 with kinesin and with VE-cadherin. However,
it is unclear whether or not VE-cadherin can directly bind to kinesin or bind through
p120 because kinesin was pulled down by immunoprecipitation with the VE-cadherin
antibody not by a p120 antibody. Thus, p120 may work as a scaffold to link VE-cadherin
and kinesin. Interestingly during normal conditions, S1P increased the interaction of
p120 with kinesin (through immunoprecipitation of VE-cadherin) within 30 min of
treatment. But during the recycling process induced by EGTA, this increased interaction
by S1P occurred as early as 5 min. These data provide evidence to support that S1P
has a dual role in VE-cadherin trafficking: one is inhibition of endocytosis; another is the
enhancement of recycling. p120 may be involved in both processes.
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